Point-of-care methadone and EDDP quantification systems and methods
The point-of-care diagnostic system using lateral flow devices for methadone and EDDP quantification addresses the challenge of delayed clinical assessments by providing rapid and accurate concentration measurements, enabling timely dosing adjustments for patients with opioid use disorder.
Patent Information
- Application Number
- PCT/US2026/028473
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-15
- Filing Date
- 2026-05-15
- Publication Date
- 2026-11-19
AI Technical Summary
Current clinical practices for assessing methadone metabolic profiles in patients with opioid use disorder are burdensome and lack timely quantitative information for real-time clinical decision-making, as they require multiple blood draws and laboratory analysis, which can introduce delays.
A point-of-care diagnostic system using lateral flow devices for quantifying methadone and its metabolite EDDP in blood or plasma samples, employing a pre-mix buffer, chase buffer, and labeled antibodies to generate rapid quantitative results through a lateral flow device with detection zones and a data analyzer for methadone concentration determination.
Provides rapid, accurate quantification of methadone and EDDP concentrations within 30 minutes, allowing clinicians to make informed dosing adjustments and categorizing patients into metabolic categories based on methadone to metabolite ratios, supporting personalized treatment plans.
Smart Images

Figure US2026028473_19112026_PF_FP_ABST
Abstract
Description
Attorney Docket No. 132621 -0010WO01POINT-OF-CARE METHADONE AND EDDP QUANTIFICATION SYSTEMS AND METHODS CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority to U.S. Application No. 63 / 806,333, filed May 15, 2025, which is hereby incorporated by reference in its entirety.STATEMENT AS TO FEDERALLY SPONSORED RESEARCH
[0002] This invention was made with Government support under DA059627 awarded by the National Institutes of Health. The Government has certain rights in this invention.FIELD OF INVENTION
[0003] The present disclosure relates to point-of-care diagnostic systems and methods for quantifying drug concentrations in biological samples, and more particularly to lateral flow devices and associated methods for quantifying methadone and its metabolite EDDP in blood or plasma samples to assist in dosing decisions for patients undergoing methadone treatment for opioid use disorder.BACKGROUND
[0004] Opioid use disorder represents a significant public health challenge, and methadone maintenance treatment (MMT) has been used for decades as an effective therapeutic approach. Methadone is a long-acting opioid agonist that can help reduce cravings and withdrawal symptoms in patients with opioid dependence. When properly dosed, methadone treatment can support patient recovery and reduce the risks associated with illicit opioid use.
[0005] However, achieving optimal methadone dosing for individual patients remains challenging. Patients exhibit substantial variability in how they metabolize methadone, with genetic and physiological differences leading to wide variations in serum drug levels for any given dose. Some patients metabolize methadone rapidly, which can lead to inadequate therapeutic concentrations and breakthrough withdrawal symptoms. Other patients metabolize methadone slowly, which may result in drug accumulation and associated adverse effects. This metabolic variability can contribute to poor treatment outcomes and patient dropout from treatment programs.- 1 - 132621-0010W001 / 10715598.10Attomey Docket No. 132621 -0010WO01
[0006] Current clinical practices for assessing a patient's metabolic profile typically involve measuring peak and trough serum levels of methadone. This approach generally requires multiple blood draws at specific time intervals, which can be burdensome for patients and clinicians alike. Additionally, blood samples are often sent to specialty laboratories for analysis, which can introduce delays of several days before results are available. During this time, clinicians may lack the timely information needed to make informed dosing adjustments.
[0007] Methadone is metabolized in the body to form various metabolites, including 2-ethylidene-l,5-dimethyl-3,3-diphenylpyrrolidine (EDDP). The relationship between methadone and its metabolites can provide information about a patient's metabolic status. However, existing approaches for measuring these analytes may not provide results in a timeframe that supports real-time clinical decision-making.
[0008] Point-of-care diagnostic devices offer the potential for rapid testing at the site of patient care. Lateral flow immunoassays, for example, have been used in various diagnostic applications due to their relative simplicity and speed. However, adapting such technologies for quantitative measurement of specific analytes in complex biological matrices such as blood or plasma can present technical challenges.
[0009] Accordingly, there remains a need for improved systems and methods that can provide timely quantitative information about methadone and its metabolites to support clinical decision-making in the treatment of patients with opioid use disorder.SUMMARY
[0010] In one aspect of the present disclosure, provided herein is a method for quantifying methadone in a blood or plasma sample. The method comprises obtaining a blood or plasma sample from a subject. The method further comprises contacting the blood or plasma sample: (i) with a pre-mix buffer to form a pre-mixed sample and loading the pre-mixed sample onto a lateral flow device; (ii) directly onto a lateral flow device followed by a chase buffer; or (iii) directly onto a lateral flow device. The lateral flow device comprises a flow path for receiving a fluid sample, a sample receiving zone coupled to the flow path, a labeled anti-methadone antibody coupled to the flow path upstream of a first detection zone, and a first detection zone coupled to the flow path downstream of the sample receiving zone and comprising an immobilized methadone-bovine serum albumin (BSA) conjugate. The methadone-BSA conjugate has a methadone to B SA conjugation ratio within the range of 15 : 1 to 1 : 1. The labeled anti-methadone antibody that is unbound to methadone is configured to flow in the flow path to - 2 - 132621-0010W001 / 10715598.10Attorney Docket No. 132621 -0010WO01the first detection zone, is captured at the first detection zone, and emits a detectable signal. The labeled anti-methadone antibody that is specifically bound to the methadone in the blood or plasma sample is configured to flow in the flow path past the first detection zone when the fluid sample is received on the lateral flow device. The method further comprises detecting a signal intensity from the labeled anti-methadone antibody bound to immobilized methadone :-B SA conjugate in the first detection zone. The method further comprises determining the concentration of methadone based on a detected signal intensity from the first detection zone by converting the measured detected signal intensity to a methadone concentration using a dose response curve.
[0011] According to other aspects of the present disclosure, the method may include one or more of the following features. A pre-mix buffer, chase buffer, and / or flow path chemistry dispensed upstream of the detection zone of the lateral flow device may comprise one or more of a blocking protein, a surfactant, a chelating agent, a salt, and a buffering agent. The pre-mix running buffer may comprise phosphate buffered saline, Tween-20, and a preservative at a pH of 7.0 to 8.0. The concentration of methadone may be quantified with a coefficient of variation (CV) of less than a value selected from the group consisting of 20%, 15%, 10%, and 5%. The lateral flow device may further comprise a control-line zone, wherein the labeled anti-methadone antibody that is bound to methadone present in the sample is captured at the control-line zone and emits a detectable control signal. The anti-methadone antibody may be conjugated to a detectable label comprising gold nanoparticles. The gold nanoparticles may have a diameter of approximately 40 nm. The signal intensity may be detected using a reader comprising a light source and a detector, and a data analyzer configured to convert the detected signal intensity to the methadone concentration based on the dose response curve. The methadone concentration quantified may be within a range of 75 ng / mL to 1600 ng / mL. The blood or plasma sample may be a fingerstick capillary blood sample. The sample volume may be approximately 5 pL of plasma mixed with approximately 95 pL of pre-mix running buffer to form a total assay volume of approximately 100 pL. The lateral flow device may comprise a nitrocellulose membrane comprising a CN140 membrane. The lateral flow device may comprise a conjugate pad pretreated with a pretreatment buffer, wherein the pretreatment buffer comprises a surfactant, a buffering agent, and a blocking protein. The dose response curve may be generated using a four-parameter logistic (4PL) curve fit. The method may further comprise determining a methadone concentration from the dose response curve within 30 minutes or within 15 minutes of loading the sample onto the lateral flow device.- 3 - 132621-0010W001 / 10715598.10Attomey Docket No. 132621 -0010WO01
[0012] According to another aspect of the present disclosure, a test system for quantifying methadone in a blood or plasma sample is provided. The test system comprises a kit comprising a pre-mix running buffer configured to form a pre-mixed sample when contacted with a blood or plasma sample. The test system further comprises a lateral flow device comprising a flow path for receiving a fluid sample, a sample receiving zone coupled to the flow path, a labeled anti-methadone antibody coupled to the flow path upstream of a first detection zone, and a first detection zone coupled to the flow path downstream of the sample receiving zone and comprising an immobilized methadone-bovine serum albumin (BSA) conjugate. The methadone-BSA conjugate has a methadone to BSA conjugation ratio within the range of 15:1 to 1:1. The test system further comprises a reader comprising a light source and a detector, and a data analyzer.
[0013] According to other aspects of the present disclosure, the test system may include one or more of the following features. The labeled anti-methadone antibody that is unbound to methadone may be configured to flow in the flow path to the first detection zone and be captured by the immobilized methadone: -BSA conjugate at the first detection zone and emit a detectable signal. The labeled anti-methadone antibody specifically bound to the methadone in the blood or plasma sample may be configured to flow in the flow path past the first detection zone when the fluid sample is received on the lateral flow device. The lateral flow device may further comprise a labeled anti-EDDP antibody coupled to the flow path upstream of a second detection zone, and a second detection zone coupled to the flow path downstream of the sample receiving zone and comprising an immobilized EDDP-BSA conjugate having an EDDP to BSA conjugation ratio within the range of 15:1 to 1:1. The labeled anti-EDDP antibody that is unbound to EDDP may be configured to flow in the flow path to the second detection zone, be captured at the second detection zone, and emit a detectable signal. The data analyzer may be configured to calculate a methadone to metabolite ratio (MMR) based on a concentration of methadone detected at the first detection zone and a concentration of EDDP detected at the second detection zone. The reader may comprise an iPeak reader configured to generate an iPeak Area Score corresponding to the signal intensity at each detection zone. The test system may further comprise a lancet for obtaining a capillary blood sample from a fingertip of a subject. The data analyzer may be configured to assign the patient to a metabolic category selected from the group consisting of ultra-rapid metabolizer (URM), extensive metabolizer (EM), intermediate metabolizer (IM), and ultra-slow metabolizer (USM) based on the MMR. The data analyzer may be configured to analyze reader data using a four-parameter logistic (4PL) curve- 4 - 132621-0010W001 / 10715598.10Attorney Docket No. 132621 -0010WO01fit to generate the dose response curve. The lateral flow device may further comprise a sample pad comprising a blood separation pad configured to separate cellular components from plasma. The lateral flow device may be configured to quantify methadone within a range of 75 ng / mL to 1600 ng / mL and EDDP within a range of 5 ng / mL to 500 ng / mL.
[0014] According to another aspect of the present disclosure, a lateral flow test strip device for quantifying methadone and EDDP in a blood or plasma sample is provided. The device comprises a flow path for receiving a fluid sample, a sample receiving zone coupled to the flow path, a labeled anti-methadone antibody coupled to the flow path upstream of a first detection zone, and a first detection zone coupled to the flow path downstream of the sample receiving zone and comprising an immobilized methadone-BSA conjugate. The methadone-BSA conjugate has a methadone to BSA conjugation ratio within the range of 15 : 1 to 1:1. The device further comprises a labeled anti-EDDP antibody coupled to the flow path upstream of a second detection zone, and a second detection zone coupled to the flow path downstream of the sample receiving zone and comprising an immobilized EDDP-BSA conjugate having an EDDP to BSA conjugation ratio within the range of 15:1 to 1:1. The labeled anti-methadone antibody that is unbound to methadone is configured to flow in the flow path to the first detection zone and is captured by the immobilized methadone-BSA conjugate at the first detection zone and emits a detectable signal. The labeled anti-methadone antibody specifically bound to the methadone in the blood or plasma sample is configured to flow in the flow path past the first detection zone when the fluid sample is received on the lateral flow device.
[0015] According to other aspects of the present disclosure, the lateral flow test strip device may include one or more of the following features. The labeled anti-EDDP antibody that is unbound to EDDP may be configured to flow in the flow path to the second detection zone, be captured at the second detection zone, and emit a detectable signal. The labeled anti-EDDP antibody that is specifically bound to the EDDP in the blood or plasma sample may be configured to flow in the flow path past the second detection zone when the fluid sample is received on the lateral flow device. The device may further comprise a control-line zone positioned downstream of the first detection zone and the second detection zone, wherein the control-line zone comprises a goat anti-mouse antibody configured to capture labeled antibody that has flowed through the first detection zone and the second detection zone. The labeled anti-methadone antibody and the labeled anti-EDDP antibody may each be conjugated to gold nanoparticles. The gold nanoparticles may have a diameter of approximately 40 nm. The device may further comprise a conjugate pad configured to receive and release the labeled anti- - 5 - 132621-0010W001 / 10715598.10Attomey Docket No. 132621 -0010WO01methadone antibody and the labeled anti-EDDP antibody, wherein the conjugate pad is pretreated with a pretreatment buffer configured to facilitate release of the labeled antibodies when a sample is applied to the lateral flow test strip device. The conjugate pad may comprise an Ahlstrom 8980 conjugate pad comprising chopped glass fibers with a binder. The pretreatment buffer may comprise Tergitol, HEPES, sodium tetraborate decahydrate, and BSA. The first detection zone may be positioned upstream of the second detection zone along the flow path, or the second detection zone may be positioned upstream of the first detection zone along the flow path. The device may further comprise a nitrocellulose membrane having a width of approximately 25 mm, wherein the first detection zone and the second detection zone are positioned on the nitrocellulose membrane. The device may further comprise a sample pad having a length of approximately 15 mm and an absorbent pad having a length of approximately 20 mm. The immobilized methadone-BSA conjugate may be striped onto a nitrocellulose membrane at a concentration of approximately 0.25 mg / mL to approximately 0.5 mg / mL. The immobilized EDDP-BSA conjugate may be striped onto a nitrocellulose membrane at a concentration of approximately 0.125 mg / mL to approximately 0.5 mg / mL.
[0016] According to another aspect of the present disclosure, a kit for point-of-care quantification of methadone and EDDP in a blood or plasma sample is provided. The kit comprises a lateral flow test strip device comprising a flow path, a sample receiving zone, a labeled anti-methadone antibody upstream of a first detection zone comprising an immobilized methadone-BSA conjugate having a methadone to BSA conjugation ratio within the range of 15:1 to 1:1, a labeled anti-EDDP antibody upstream of a second detection zone comprising an immobilized EDDP-BSA conjugate having an EDDP to BSA conjugation ratio within the range of 15:1 to 1:1. The kit further comprises a pre-mix running buffer configured to be contacted with the blood or plasma sample to form a pre-mixed sample prior to loading onto the lateral flow test strip device. The kit further comprises instructions for use.
[0017] According to other aspects of the present disclosure, the kit may include one or more of the following features. The kit may further comprise a reader comprising a light source and a detector, and a data analyzer configured to convert detected signal intensity to analyte concentration based on a dose response curve. The kit may further comprise a lancet for obtaining a capillary blood sample from a fingertip of a subject. The pre-mix running buffer may comprise a carbonate buffer, a salt, a chelating agent, and a surfactant. The data analyzer may be configured to calculate a methadone to metabolite ratio (MMR) based on a concentration of methadone detected at the first detection zone and a concentration of EDDP detected at the - 6 - 132621-0010W001 / 10715598.10Attomey Docket No. 132621 -0010WO01second detection zone. The data analyzer may be configured to assign a patient to a metabolic category selected from the group consisting of ultra-rapid metabolizer (URM), extensive metabolizer (EM), intermediate metabolizer (IM), and ultra-slow metabolizer (USM) based on the MMR. The lateral flow test strip device may further comprise a control-line zone positioned downstream of the first detection zone and the second detection zone. The labeled antimethadone antibody and the labeled anti-EDDP antibody may each be conjugated to gold nanoparticles.
[0018] According to another aspect of the present disclosure, a method for quantifying EDDP in a blood or plasma sample is provided. The method comprises obtaining a blood or plasma sample from a subject. The method further comprises contacting the blood or plasma sample: (i) with a pre-mix buffer to form a pre-mixed sample and loading the pre-mixed sample onto a lateral flow device; (ii) directly onto a lateral flow device followed by a chase buffer; or (iii) directly onto a lateral flow device. The lateral flow device comprises a flow path for receiving a fluid sample, a sample receiving zone coupled to the flow path, a labeled anti-EDDP antibody coupled to the flow path upstream of a detection zone, and a detection zone coupled to the flow path downstream of the sample receiving zone and comprising an immobilized EDDP-bovine serum albumin (BSA) conjugate. The EDDP-BSA conjugate has an EDDP to BSA conjugation ratio within the range of 15:1 to 1:1. The labeled anti-EDDP antibody that is unbound to EDDP is configured to flow in the flow path to the detection zone, is captured at the detection zone, and emits a detectable signal. The labeled anti-EDDP antibody that is specifically bound to the EDDP in the blood or plasma sample is configured to flow in the flow path past the detection zone when the fluid sample is received on the lateral flow device. The method further comprises detecting a signal intensity from the labeled anti-EDDP antibody bound to immobilized EDDP-BSA conjugate in the detection zone. The method further comprises determining the concentration of EDDP based on a detected signal intensity from the detection zone by converting the measured detected signal intensity to an EDDP concentration using a dose response curve.
[0019] According to other aspects of the present disclosure, the method for quantifying EDDP may include one or more of the following features. The concentration of EDDP may be quantified with a coefficient of variation (CV) of less than a value selected from the group consisting of: 20%, 15%, 10%, and 5%. The lateral flow device may further comprise a controlline zone, wherein the labeled anti-EDDP antibody that is bound to EDDP present in the sample is captured at the control-line zone and emits a detectable control signal. The anti-EDDP - 7 - 132621-0010W001 / 10715598.10Attorney Docket No. 132621 -0010WO01antibody may be conjugated to a detectable label comprising gold nanoparticles. The signal intensity may be detected using a reader comprising a light source and a detector, and a data analyzer configured to convert the detected signal intensity to the EDDP concentration based on the dose response curve. The EDDP concentration quantified may be within a range of 5 ng / mL to 500 ng / mL.
[0020] According to another aspect of the present disclosure, a test system for quantifying EDDP in a blood or plasma sample is provided. The test system comprises a kit comprising a pre-mix running buffer configured to form a pre-mixed sample when contacted with a blood or plasma sample. The test system further comprises a lateral flow device comprising a flow path for receiving a fluid sample, a sample receiving zone coupled to the flow path, a labeled anti-EDDP antibody coupled to the flow path upstream of a detection zone, and a detection zone coupled to the flow path downstream of the sample receiving zone and comprising an immobilized EDDP -bovine serum albumin (BSA) conjugate. The EDDP -B SA conjugate has an EDDP to BSA conjugation ratio within the range of 15:1 to 1:1. The test system further comprises a reader comprising a light source and a detector, and a data analyzer.
[0021] According to other aspects of the present disclosure, the test system for quantifying EDDP may include one or more of the following features. The labeled anti-EDDP antibody that is unbound to EDDP may be configured to flow in the flow path to the detection zone and be captured by the immobilized EDDP -BSA conjugate at the detection zone and emit a detectable signal. The labeled anti-EDDP antibody specifically bound to the EDDP in the blood or plasma sample may be configured to flow in the flow path past the detection zone when the fluid sample is received on the lateral flow device.
[0022] According to another aspect of the present disclosure, a lateral flow test strip device for quantifying EDDP in a blood or plasma sample is provided. The device comprises a flow path for receiving a fluid sample, a sample receiving zone coupled to the flow path, a labeled anti-EDDP antibody coupled to the flow path upstream of a detection zone, and a detection zone coupled to the flow path downstream of the sample receiving zone and comprising an immobilized EDDP -bovine serum albumin (BSA) conjugate. The EDDP -BSA conjugate has an EDDP to B SA conjugation ratio within the range of 15 : 1 to 1 : 1. The labeled anti-EDDP antibody that is unbound to EDDP is configured to flow in the flow path to the detection zone and is captured by the immobilized EDDP -BSA conjugate at the detection zone and emits a detectable signal. The labeled anti-EDDP antibody specifically bound to the EDDP in the blood or plasma- 8 - 132621-0010W001 / 10715598.10Attomey Docket No. 132621 -0010WO01sample is configured to flow in the flow path past the detection zone when the fluid sample is received on the lateral flow device.BRIEF DESCRIPTION OF FIGURES
[0023] Non-limiting and non-exhaustive examples are described with reference to the following figures.
[0024] FIG. 1 illustrates a simplified pharmacokinetic model for methadone metabolism and derivation of a methadone to metabolite ratio (MMR) in accordance with aspects of the present disclosure. The pharmacokinetic model provides the theoretical basis for interpreting MMR values obtained from the point-of-care methadone and EDDP quantification systems described herein.
[0025] FIG. 2 depicts a graph of a simulated methadone to metabolite ratio (MMR) as a function of time in accordance with aspects of the present disclosure. The vertical axis represents the MMR value, ranging from approximately 10 to 50. The horizontal axis represents time measured in days, extending from 0 to approximately 20 days.
[0026] FIG. 3 illustrates a schematic diagram of a lateral flow test strip device 100 for quantifying methadone and / or EDDP in a blood or plasma sample in accordance with one embodiment of the present disclosure. The lateral flow test strip device 100 comprises a flow path for receiving a fluid sample, with components arranged sequentially along the flow path from a sample application end to an absorbent end.
[0027] FIG. 4 depicts a dose-response curve for a methadone lateral flow assay showing iPeak Area Score as a function of methadone concentration, according to aspects of the present disclosure.
[0028] FIG. 5 depicts a dose-response curve for an EDDP lateral flow assay showing iPeak Area Score as a function of EDDP concentration, according to aspects of the present disclosure.
[0029] FIG. 6 depicts a comparison of dose-response curves for a methadone lateral flow assay in plasma and serum matrices, according to aspects of the present disclosure. The table shows performance for the serum curve only.- 9 - 132621-0010W001 / 10715598.10Attorney Docket No. 132621 -0010WO01
[0030] FIG. 7 depicts a comparison of dose-response curves for an EDDP lateral flow assay in plasma and serum matrices, according to aspects of the present disclosure. The table shows performance for the serum curve only.
[0031] FIG. 8 illustrates a schematic diagram of a particular embodiment of a lateral flow test strip device.DETAILED DESCRIPTION
[0032] Provided herein are lateral flow test systems, test-strip devices, and methods for quantifying methadone and 2-ethylidene-l,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) in blood or plasma samples. EDDP is a metabolite of methadone. The lateral flow test-strip devices described herein may be based on an inhibition lateral flow format. In an inhibition lateral flow format, a labeled antibody that is unbound to a target analyte may flow along a flow path to a detection zone, where the unbound labeled antibody may be captured and emit a detectable signal. A labeled antibody that is specifically bound to the target analyte present in a sample may flow past the detection zone without being captured. Accordingly, the signal intensity at the detection zone may be inversely related to the concentration of the target analyte in the sample.
[0033] The lateral flow devices and associated test systems described herein may be configured for point-of-care diagnostic applications. Point-of-care testing may allow for rapid quantification of methadone and EDDP concentrations at the site of patient care, such as in an opioid treatment program (OTP) setting. In some cases, the test systems may provide quantitative results that assist clinicians in making dosing decisions for patients undergoing methadone maintenance treatment (MMT) for opioid use disorder.
[0034] As used herein, the term "lateral flow device" refers to a diagnostic device that utilizes capillary flow to transport a fluid sample along a flow path through one or more functional zones. A lateral flow device may include, but is not limited to, a lateral flow test strip, a lateral flow test strip device, a lateral flow cassette, a lateral flow cartridge, or a lateral flow test strip housed within a device housing. A lateral flow device may comprise a sample pad, a conjugate pad, a nitrocellulose membrane, and an absorbent pad arranged sequentially along the flow path.
[0035] As used herein, the term "detection zone" refers to a region on the flow path of a lateral flow device where a specific binding interaction occurs between a labeled antibody and an immobilized capture reagent, resulting in a detectable signal. A detection zone may also be- 10 - 132621-0010W001 / 10715598.10Attorney Docket No. 132621 -0010WO01referred to as a "test line" or "T-line." A first detection zone may comprise an immobilized methadone-BSA conjugate for detection of methadone. A second detection zone may comprise an immobilized EDDP-BSA conjugate for detection of EDDP.
[0036] As used herein, the term "conjugation ratio" refers to the molar ratio of materials at the start of a conjugation reaction. For example, a methadone to BSA conjugation ratio of 15:1 refers to a ratio of 15 moles of methadone to 1 mole of BSA at the start of the conjugation reaction used to prepare the methadone-BSA conjugate. Similarly, an EDDP to BSA conjugation ratio of 15 : 1 refers to a ratio of 15 moles of EDDP to 1 mole of BSA at the start of the conjugation reaction used to prepare the EDDP-BSA conjugate.
[0037] In other embodiments, the methadone-BSA conjugate has a methadone:BSA conjugation ratio selected from the group consisting of: equal to or less than 100:1, 90:1, 80:1, 70:1, 60:1, 50:1, 40:1, 30:1, 25:1, 20:1, 15:1, 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, and equal to or less than 1:1; or the conjugation ratio is within the range 100: 1 to 1 : 1, 90: 1 to 1 : 1, 80: 1 to 1:1, 70:1 to 1:1, 60:1 to 1:1, 50:1 to 1:1, 40:1 to 1:1, 30:1 to 1:1, 25:1 to 1:1, 20:1 to 1:1, 15:1 to 1:1, 10:1 to 1:1, 9:1 to 1:1, 8:1 to 1:1, 7:1 to 1:1, 6:1 to 1:1, and 5:1 to 1:1. In a particular embodiment, the EDDP-BSA conjugate has an EDDP to BSA conjugation ratio within the range of 15:1 to 1:1.
[0038] As used herein, the term "labeled" when used in reference to an antibody (e.g., "labeled anti-methadone antibody" or "labeled anti-EDDP antibody") refers to an antibody that is conjugated to, attached to, or otherwise associated with a detectable label. A detectable label may include, but is not limited to, a metal nanoparticle (such as a gold nanoparticle), a polymeric particle, a latex microparticle, a lanthanide-doped particle, a fluorophore, an enzyme, a chemiluminescent moiety, a quantum dot, a carbon nanoparticle, a silica nanoparticle, or a magnetic particle.
[0039] As used herein, the term "dose response curve" refers to a mathematical relationship between the concentration of an analyte in a sample and the signal intensity measured at a detection zone. In an inhibition lateral flow format, the dose response curve may exhibit an inverse relationship, wherein higher analyte concentrations result in lower signal intensities at the detection zone. The dose response curve may be generated using standard samples containing known concentrations of the analyte and may be used to interpolate analyte concentrations from measured signal intensities in unknown samples.- 11 - 132621-0010W001 / 10715598.10Attorney Docket No. 132621 -0010WO01
[0040] As used herein, the term "pre-mix buffer" or "pre-mix running buffer" refers to a buffer solution that is contacted with a blood or plasma sample to form a pre-mixed sample prior to loading onto a lateral flow device. The pre-mix buffer may be configured to dilute the sample, facilitate flow of the sample through the lateral flow device, reduce non-specific binding, and / or stabilize assay reagents.
[0041] As used herein, the term "chase buffer" refers to a buffer solution that is applied to a lateral flow device after a blood or plasma sample has been loaded directly onto the device. The chase buffer may be configured to facilitate flow of the sample through the lateral flow device and carry the sample through the flow path to the detection zones.
[0042] As used herein, the term "blood or plasma sample" refers to a biological sample obtained from a subject that contains blood or a blood-derived component. A blood or plasma sample may include, but is not limited to, whole blood, plasma, serum, capillary blood obtained via fingerstick, or venous blood obtained via venipuncture.
[0043] As used herein, the term "methadone to metabolite ratio" or "MMR" refers to the ratio of the concentration of methadone to the concentration of its metabolite EDDP (2-ethylidene-l,5-dimethyl-3,3-diphenylpyrrolidine) in a blood or plasma sample. The MMR may be calculated by dividing the measured methadone concentration by the measured EDDP concentration. The MMR may represent the net metabolism of methadone in a patient and may be used to assign a patient to a metabolic category.
[0044] As used herein, the term "metabolic category" refers to a classification of a patient's methadone metabolism rate based on the methadone to metabolite ratio (MMR). Metabolic categories may include: ultra-rapid metabolizer (URM) with an MMR less than 5; extensive metabolizer (EM) with an MMR greater than or equal to 5 and less than 12; intermediate metabolizer (IM) with an MMR greater than or equal to 12 and less than 16; and ultra-slow metabolizer (USM) with an MMR greater than or equal to 16.
[0045] As used herein, the term "four-parameter logistic curve fit" or "4PL curve fit" refers to a mathematical model used to fit dose response data to a sigmoidal curve defined by four parameters: a minimum asymptote, a maximum asymptote, an inflection point corresponding to the concentration at which the response is halfway between the minimum and maximum asymptotes, and a Hill slope describing the steepness of the curve. The 4PL curve fit may be- 12 - 132621-0010W001 / 10715598.10Attorney Docket No. 132621 -0010WO01used to generate a dose response curve from standard concentrations and to interpolate analyte concentrations from measured signal intensities.
[0046] As used herein, the term "coefficient of variation" or "CV" refers to a measure of the precision of replicate measurements, calculated as the ratio of the standard deviation to the mean of the replicate measurements, expressed as a percentage. A lower CV value indicates higher precision.
[0047] As used herein, the term "control-line zone" refers to a region on the flow path of a lateral flow device positioned downstream of the detection zone or detection zones. The controlline zone is configured to capture labeled antibody that has flowed through the detection zones, thereby providing confirmation that the sample has flowed properly through the lateral flow device and that the assay reagents are functioning as expected. The control-line zone may also be referred to as a "control line" or "C-line."
[0048] As used herein, the term "immobilized" when used in reference to a conjugate (e.g., "immobilized methadone-BSA conjugate" or "immobilized EDDP-BSA conjugate") refers to a conjugate that is fixed, attached, or otherwise bound to a surface of the lateral flow device, such as the nitrocellulose membrane, such that the conjugate does not flow with the sample along the flow path. The immobilized conjugate may be applied to the nitrocellulose membrane by striping at a defined concentration and stripe rate.
[0049] As used herein, the term "flow path chemistry" refers to chemical compositions that are dispensed onto or incorporated into components of the lateral flow device upstream of the detection zone. Flow path chemistry may include compositions applied to the sample pad, the conjugate pad, or other regions of the flow path. Flow path chemistry may comprise one or more of blocking proteins, saccharides, surfactants, polymers, chaotropic agents, chelating agents, salts, and buffering agents configured to facilitate sample flow, reduce non-specific binding, improve conjugate release, and / or stabilize reagents.
[0050] In some aspects, the lateral flow devices may be configured to quantify methadone in a blood or plasma sample. In some aspects, the lateral flow devices may be configured to quantify EDDP in a blood or plasma sample. In some aspects, multiplex lateral flow devices may be configured to quantify both methadone and EDDP in a single blood or plasma sample. The quantification of both methadone and EDDP may allow for determination of a methadone to metabolite ratio (MMR), which may provide information about a patient's metabolic profile.- 13 - 132621-0010W001 / 10715598.10Attorney Docket No. 132621 -0010WO01
[0051] Referring to FIG. 1, the top portion of the figure depicts a sequential reaction scheme representing the metabolization pathway of methadone. Methadone undergoes metabolization, governed by rate constant km, to form a metabolite (EDDP). The metabolite subsequently undergoes renal elimination, governed by rate constant ke, to produce the metabolite found in urine (Metaboliteurine).
[0052] The middle portion of FIG. 1 depicts the steady state conditions for the pharmacokinetic model. At steady state, the derivative of the metabolite concentration with respect to time (d c(Metabolite) / dt) equals zero. This relationship is valid when the renal elimination rate constant ke is much greater than the metabolization rate constant km (i.e., ke » km).
[0053] The bottom portion of FIG. 1 depicts the MMR equation. The MMR is expressed as the ratio of the concentration of methadone to the concentration of metabolite: metabolite:MMR=c(Methadone) / c(Metabolite)
[0054] Under the steady state approximation, this ratio is approximately equal to the ratio of the renal elimination rate constant to the metabolization rate constant:MMR~ke / km
[0055] The pharmacokinetic model illustrated in FIG. 1 provides the foundation for using MMR values to assess individual metabolic profiles. The MMR represents the net metabolism and can be used to assign a specific metabolic category to each patient. In one embodiment, MMR values are divided into four established metabolic categories: ultra-rapid metabolizer (URM) with MMR less than 5; extensive metabolizer (EM) with MMR greater than or equal to 5 and less than 12; intermediate metabolizer (IM) with MMR greater than or equal to 12 and less than 16; and ultra-slow metabolizer (USM) with MMR greater than or equal to 16. Underdosing typically occurs in the URM category, while excessive dosing can occur in the IM and USM categories.
[0056] Referring to FIG. 2, a solid curve demonstrates the dynamic behavior of the MMR over time following initiation of methadone treatment. The simulation was performed using a metabolization rate constant km = 0.001 hr-1, consistent with literature-reported half-life values of methadone, and a renal elimination rate constant ke = 0.01 hr-1, chosen to reproduce a typical experimental MMR value of approximately 10 at steady state.- 14 - 132621-0010W001 / 10715598.10Attorney Docket No. 132621 -0010WO01
[0057] As shown in FIG. 2, the MMR begins at a high value of approximately 50 at time zero (initiation of treatment) and exhibits a steep exponential decay during the initial days following the start of methadone treatment. The curve descends rapidly through the first approximately 5 days, then gradually levels off as it approaches a steady state value. A horizontal dashed line represents the steady state MMR value of approximately 10 that the system approaches asymptotically.
[0058] The graph in FIG. 2 demonstrates that the MMR varies drastically within the initial time period after methadone treatment has been started. It takes up to approximately 10 days before the MMR values level off and approach the steady state limit value. This time-dependent behavior has important clinical implications for the point-of-care test systems described herein.
[0059] In one embodiment, the lateral flow devices and software systems for quantifying methadone and EDDP are configured to measure this time-dependent change in MMR daily when the patient visits the clinic. The clinicians receive a daily MMR that is indicative of the patient's metabolic response to methadone. Following the MMR value as it approaches its steady state number provides important initial dosing feedback and assistance for the clinician.
[0060] In one embodiment, the data analyzer is configured to record all relevant numerical data for each patient, perform linear regression calculations, and deliver a day-by-day evaluation of the patient's assigned metabolic category. Based on the pharmacokinetic model illustrated in FIGS. 1 and 2, the MMR test may be applied at least every other day during the first 10 days of induction, followed by once a month for the next three months, and then quarterly thereafter.
[0061] The test systems described herein may include a lateral flow test-strip device, a premix running buffer, and a reader. In some cases, a blood or plasma sample may be contacted with the pre-mix running buffer to form a pre-mixed sample prior to loading onto the lateral flow device. The reader may include a light source and a detector for detecting signal intensity from the lateral flow device. A data analyzer may be configured to convert detected signal intensity to analyte concentration based on a dose response curve.
[0062] In some aspects, the lateral flow devices may be configured for use with whole blood samples. A blood separation sample pad may be configured to receive whole blood samples and separate cellular components from plasma before the sample flows through a conjugate pad and onto a membrane. In some aspects, the lateral flow devices may be configured for use with plasma samples.- 15 - 132621-0010W001 / 10715598.10Attorney Docket No. 132621 -0010WO01
[0063] The point-of-care quantification of methadone and EDDP may provide objective feedback on a patient's methadone dosing based on pharmacokinetic information. In some cases, individual pharmacokinetic data may be combined with other clinical information to determine personalized dose adjustments for patients in the induction or maintenance stages of medication assisted treatment.
[0064] The lateral flow test-strip devices described herein may include a nitrocellulose membrane that provides the flow path and detection zones for the assay. In some aspects, the nitrocellulose membrane may comprise a CN140 membrane. In some aspects, the nitrocellulose membrane may comprise a CN180Dx membrane. The CN140 membrane and the CN180Dx membrane may serve as alternatives for providing the flow path and detection zones in the lateral flow test-strip device.
[0065] In some cases, the nitrocellulose membrane may have a width of approximately 25 mm. The nitrocellulose membrane may be configured to support one or more detection zones, including a first detection zone comprising an immobilized methadone:BSA conjugate and, in multiplex configurations, a second detection zone comprising an immobilized EDDP:BSA conjugate. The nitrocellulose membrane may also support a control-line zone.
[0066] In some aspects, test lines and control lines may be striped onto the nitrocellulose membrane at a rate of approximately 1 pL / cm. The control line may comprise goat anti-mouse (GAM) antibody at a concentration of approximately 0.5 mg / mL. The methadone test line may comprise a methadone:BSA conjugate at a concentration ranging from approximately 0.25 mg / mL to approximately 0.5 mg / mL. The EDDP test line may comprise an EDDP:BSA conjugate at a concentration ranging from approximately 0.125 mg / mL to approximately 0.5 mg / mL.
[0067] In some cases, the CN140 membrane may provide improved visual characteristics for the detection zones compared to other membrane options. The nitrocellulose membrane may be mounted on a backing card to provide structural support for the lateral flow test-strip device. The backing card may have a length of approximately 60 mm to accommodate the nitrocellulose membrane along with the sample pad, conjugate pad, and absorbent pad components of the lateral flow test-strip device.
[0068] The lateral flow test-strip devices described herein may include a conjugate pad configured to receive and release labeled antibody conjugates. In some aspects, the conjugate- 16 - 132621-0010W001 / 10715598.10Attorney Docket No. 132621 -0010WO01pad may comprise an Ahlstrom 8980 conjugate pad (commercially avialable from Ahlsotrom, Kaukauna, WI). The Ahlstrom 8980 conjugate pad may comprise chopped glass fibers with a binder. In some cases, the Ahlstrom 8980 conjugate pad may have a wicking rate of approximately 2.2 seconds per 4 cm. In some aspects, the conjugate pad may comprise an Ahlstrom 6614 conjugate pad. The Ahlstrom 6614 conjugate pad may comprise polyester fibers with a binder. In some cases, the Ahlstrom 6614 conjugate pad may have a wicking rate of approximately 2.5 seconds per 4 cm.
[0069] In some aspects, the conjugate pad may be pretreated with a pretreatment buffer prior to application of the labeled antibody conjugates. The pretreatment buffer may be configured to facilitate release of the labeled antibody conjugates from the conjugate pad when a sample is applied to the lateral flow device. In some cases, the pretreatment buffer may be configured to reduce non-specific binding and improve flow characteristics of the labeled antibody conjugates.
[0070] In some aspects, the conjugate pad may be pretreated with a PPI pretreatment buffer. The PPI pretreatment buffer may comprise Tergitol at approximately 2% w / v, HEPES at approximately 1.192% w / v, sodium tetraborate decahydrate at approximately 0.192% w / v, and BSA at approximately 0.1% w / v. In some cases, the PPI pretreatment buffer may be used with the Ahlstrom 8980 conjugate pad for methadone quantification applications.
[0071] In some aspects, the conjugate pad may be pretreated with a PP2 pretreatment buffer. The PP2 pretreatment buffer may comprise Trizma base at approximately 1.21% w / v, BSA at approximately 0.5% w / v, and Tween 20 at approximately 0.25% w / v. In some cases, the PP2 pretreatment buffer may be used with the Ahlstrom 8980 conjugate pad.
[0072] In some aspects, the conjugate pad may be pretreated with a PP4 pretreatment buffer. The PP4 pretreatment buffer may comprise BSA at approximately 2.5%, NaCl at approximately 0.8%, Tergitol at approximately 0.42%, Na2HPC>4 at approximately 0.14%, KC1 at approximately 0.02%, and KH2PO4 at approximately 0.02%. In some cases, the PP4 pretreatment buffer may be used with the Ahlstrom 6614 conjugate pad for EDDP quantification applications.
[0073] In some aspects, the Ahlstrom 8980 conjugate pad pretreated with the PPI pretreatment buffer may be used for methadone quantification. In some cases, the Ahlstrom 8980 conjugate pad pretreated with the PPI pretreatment buffer may provide improved inhibition characteristics compared to other conjugate pad and pretreatment buffer combinations for methadone detection. In some aspects, the Ahlstrom 6614 conjugate pad pretreated with the PPI- 17 - 132621-0010W001 / 10715598.10Attorney Docket No. 132621 -0010WO01pretreatment buffer may be used for EDDP quantification. In some cases, the Ahlstrom 8980 conjugate pad pretreated with the PPI pretreatment buffer may be used for multiplex lateral flow devices configured to quantify both methadone and EDDP in a single sample.
[0074] In some aspects, the conjugate pad may have a length of approximately 10 mm. The labeled antibody conjugates may be applied to the conjugate pad at a spray rate of approximately 10 pL / cm to approximately 12 pL / cm. In some cases, the gold-labeled anti-methadone antibody conjugate may be applied at a spray rate of approximately 10 pL / cm. In some cases, the gold-labeled anti-EDDP antibody conjugate may be applied at a spray rate of approximately 10 pL / cm to approximately 12 pL / cm.
[0075] In some aspects, the labeled antibodies described herein may be conjugated to gold nanoparticles. The gold nanoparticles may have a diameter of approximately 40 nm. Gold nanoparticles of approximately 40 nm diameter may provide suitable optical properties for detection in lateral flow immunoassay applications.
[0076] In some aspects, the gold nanoparticles may be provided at various optical density (OD) levels for conjugate application. The gold conjugate may be applied at an optical density of OD5, OD7.5, or OD10. In some cases, OD5 gold conjugate may provide strong test lines with improved line quality and reduced background staining. In some cases, OD7.5 gold conjugate may be used for both methadone and EDDP detection to provide consistency between the two assays. In some cases, reducing the optical density from OD10 to OD5 may improve displacement characteristics and line aesthetics in the lateral flow device.
[0077] In some aspects, the anti-methadone antibodies and anti-EDDP antibodies may be conjugated to the gold nanoparticles using passive conjugation. Passive conjugation may involve adsorption of antibodies onto the surface of the gold nanoparticles. In some cases, passive conjugation may be performed using one or more conjugation buffers. The conjugation buffers may include 10 mM 4-hy droxy ethyl- 1 -piperazineethanesulfonic acid (HEPES) buffer at pH 7-8, 10 mM 2-(N-morpholino) ethanesulfonic acid (MES) buffer at pH 5.80, 100 mM MES buffer at pH 5.80, 10 mM [Tris(hydroxymethyl)methylamino] propane sulfonic acid (TAPS) buffer at pH 8.50, 20 mM Borate buffer at pH 8.00, 200 mM Carbonate buffer at pH 9.00, phosphate buffered saline (PBS) at pH 7.20-7.60, or 10 mM Potassium phosphate monobasic (KPOM) at pH 7.00.- 18 - 132621-0010W001 / 10715598.10Attorney Docket No. 132621 -0010WO01
[0078] In some aspects, a gold stability test may be performed to determine the minimum concentration of antibody required to stabilize the gold conjugate solution. The gold stability test may involve adding sodium chloride to the gold conjugate solution. In some cases, 10% sodium chloride may be added to the gold conjugate solution. The minimum concentration of antibody required to stabilize the gold solution may be indicated by the condition in which the color of the gold conjugate solution does not change from red to blue upon addition of the sodium chloride. A color change from red to blue may suggest that the gold conjugate has aggregated due to sub-optimal levels of antibody coating the gold nanoparticles.
[0079] In some aspects, antibodies may be diluted in the conjugation buffer to concentrations of 0, 6, 8, 10, 12, or 14 pg / mL prior to addition of the gold colloid. The gold colloid may be added to each antibody dilution to form the gold-antibody conjugate. The antibody concentration that prevents color change upon sodium chloride addition may be selected as the minimum antibody concentration for stable conjugate formation.
[0080] In some aspects, the anti-methadone antibodies and anti-EDDP antibodies may be conjugated to gold nanoparticles using passive conjugation. Passive conjugation may involve adsorption of antibodies onto the surface of gold nanoparticles. In some cases, passive conjugation may be performed using one or more conjugation buffers to facilitate the adsorption process.
[0081] In some aspects, a HEPES conjugation buffer may be used for passive conjugation of antibodies to gold nanoparticles. The HEPES conjugation buffer may comprise 10 mM 4-hy droxy ethyl- 1 -piperazineethanesulfonic acid (HEPES) at a pH of 7 to 8. The HEPES conjugation buffer may provide a near-neutral pH environment for antibody conjugation.
[0082] In some aspects, a MES conjugation buffer may be used for passive conjugation of antibodies to gold nanoparticles. The MES conjugation buffer may comprise 2-(N-morpholino) ethanesulfonic acid (MES). In some cases, the MES conjugation buffer may comprise 10 mM MES at a pH of 5.80. In some cases, the MES conjugation buffer may comprise 100 mM MES at a pH of 5.80. The 10 mM MES conjugation buffer and the 100 mM MES conjugation buffer may serve as alternatives for providing different ionic strength conditions during antibody conjugation.
[0083] In some aspects, a TAPS conjugation buffer may be used for passive conjugation of antibodies to gold nanoparticles. The TAPS conjugation buffer may comprise 10 mM- 19 - 132621-0010W001 / 10715598.10Attorney Docket No. 132621 -0010WO01[Tris(hydroxymethyl)methylamino] propane sulfonic acid (TAPS) at a pH of 8.50. The TAPS conjugation buffer may provide a slightly alkaline pH environment for antibody conjugation.
[0084] In some aspects, a borate conjugation buffer may be used for passive conjugation of antibodies to gold nanoparticles. The borate conjugation buffer may comprise 20 mM borate at a pH of 8.00. The borate conjugation buffer may provide a mildly alkaline pH environment for antibody conjugation.
[0085] In some aspects, a carbonate conjugation buffer may be used for passive conjugation of antibodies to gold nanoparticles. The carbonate conjugation buffer may comprise 200 mM carbonate at a pH of 9.00. The carbonate conjugation buffer may provide an alkaline pH environment for antibody conjugation.
[0086] In some aspects, a PBS conjugation buffer may be used for passive conjugation of antibodies to gold nanoparticles. The PBS conjugation buffer may comprise phosphate buffered saline (PBS) at a pH of 7.20 to 7.60. The PBS conjugation buffer may provide a physiological pH environment for antibody conjugation.
[0087] In some aspects, a KPOM conjugation buffer may be used for passive conjugation of antibodies to gold nanoparticles. The KPOM conjugation buffer may comprise 10 mM potassium phosphate monobasic (KPOM) at a pH of 7.00. The KPOM conjugation buffer may provide a neutral pH environment for antibody conjugation.
[0088] In some aspects, the selection of a conjugation buffer may depend on the specific antibody being conjugated and the desired conjugation characteristics. Different conjugation buffers may provide different pH environments and ionic strength conditions that may affect the efficiency of antibody adsorption onto gold nanoparticles. In some cases, the conjugation buffer may be selected based on the results of a gold stability test as described herein.
[0089] In some aspects, the gold-labeled antibody conjugate may be applied to the conjugate pad at various spray rates. The spray rate may affect the amount of labeled antibody conjugate deposited on the conjugate pad, which may in turn affect the signal intensity and assay sensitivity of the lateral flow device.
[0090] In some aspects, the gold-labeled antibody conjugate may be applied to the conjugate pad at a spray rate of approximately 8 pL / cm. The 8 pL / cm spray rate may provide a lower amount of gold conjugate on the conjugate pad. In some cases, the 8 pL / cm spray rate may be - 20 - 132621-0010W001 / 10715598.10Attorney Docket No. 132621 -0010WO01used when a reduced amount of labeled antibody conjugate is desired for a particular assay configuration.
[0091] In some aspects, the gold-labeled antibody conjugate may be applied to the conjugate pad at a spray rate of approximately 10 pL / cm. The 10 pL / cm spray rate may provide a moderate amount of gold conjugate on the conjugate pad. In some cases, the 10 pL / cm spray rate may be used for methadone quantification applications. In some cases, the gold-labeled anti-methadone antibody conjugate may be applied at a spray rate of approximately 10 pL / cm.
[0092] In some aspects, the gold-labeled antibody conjugate may be applied to the conjugate pad at a spray rate of approximately 12 pL / cm. The 12 pL / cm spray rate may provide a higher amount of gold conjugate on the conjugate pad compared to the 8 pL / cm and 10 pL / cm spray rates. In some cases, the 12 pL / cm spray rate may be used for EDDP quantification applications. In some cases, the gold-labeled anti-EDDP antibody conjugate may be applied at a spray rate of approximately 12 pL / cm. In some cases, the 12 pL / cm spray rate may be used in combination with a lower test line concentration to shift the assay range toward lower analyte concentrations.
[0093] In some aspects, the selection of the spray rate may depend on the target analyte and the desired assay range. In some cases, different spray rates may be used for methadone and EDDP detection in a multiplex lateral flow device. In some cases, the gold-labeled anti-methadone antibody conjugate may be applied at a spray rate of approximately 10 pL / cm and the gold-labeled anti-EDDP antibody conjugate may be applied at a spray rate of approximately 12 pL / cm on the same conjugate pad for multiplex quantification of both methadone and EDDP.
[0094] In some aspects, the lateral flow devices described herein may include an anti-methadone antibody conjugated to gold nanoparticles for detection of methadone in blood or plasma samples. The anti-methadone antibody may be a monoclonal antibody. In some cases, the anti-methadone antibody may be selected from one or more commercially available anti-methadone antibody reagents suitable for gold conjugation.
[0095] In some aspects, the anti-methadone antibody may comprise a C2791N anti-methadone antibody. The C2791N anti-methadone antibody may be a mouse anti-methadone monoclonal antibody available from Creative Diagnostics under catalog number DMAB7650. The C2791N anti-methadone antibody may be conjugated to gold nanoparticles using passive conjugation as described herein.- 21 - 132621-0010W001 / 10715598.10Attorney Docket No. 132621 -0010WO01
[0096] In some aspects, the anti -methadone antibody may comprise an HM384 antimethadone antibody. The HM384 anti-methadone antibody may be a methadone antibody available from Medix Biochemica. The HM384 anti-methadone antibody may be conjugated to gold nanoparticles using passive conjugation as described herein.
[0097] In some aspects, the anti-methadone antibody may comprise an ABMTD-0402 anti-methadone antibody. The ABMTD-0402 anti-methadone antibody may be a monoclonal antibody against methadone, clone 2, available from Fortis / Arista. The ABMTD-0402 anti-methadone antibody may be conjugated to gold nanoparticles using passive conjugation as described herein.
[0098] In some aspects, the selection of the anti-methadone antibody may depend on the specific assay configuration and performance characteristics desired. In some cases, different anti-methadone antibodies may provide different binding characteristics and assay performance when paired with different methadone:BSA conjugate test line reagents. In some cases, the anti-methadone antibody may be selected based on reagent pair testing to identify combinations that provide suitable inhibition characteristics for quantitative methadone detection.
[0099] In some aspects, the anti-methadone antibody may be conjugated to 40 nm gold nanoparticles. The gold-labeled anti-methadone antibody conjugate may be prepared using passive conjugation in one or more conjugation buffers as described herein. In some cases, the gold-labeled anti-methadone antibody conjugate may be applied to the conjugate pad at an optical density of OD5, OD7.5, or OD10. In some cases, the gold-labeled anti-methadone antibody conjugate may be applied to the conjugate pad at an optical density of OD7.5.
[0100] In some aspects, the lateral flow devices described herein may include an anti-EDDP antibody conjugated to gold nanoparticles for detection of EDDP in blood or plasma samples. The anti-EDDP antibody may be a monoclonal antibody. In some cases, the anti-EDDP antibody may be selected from one or more commercially available anti-EDDP antibody reagents suitable for gold conjugation.
[0101] In some aspects, the anti-EDDP antibody may comprise an H12417N anti-EDDP antibody. The H12417N anti-EDDP antibody may be a mouse anti-EDDP monoclonal antibody available from Creative Diagnostics under catalog number DMAB3910. The H12417N anti-EDDP antibody may be conjugated to gold nanoparticles using passive conjugation as described herein.- 22 - 132621-0010W001 / 10715598.10Attorney Docket No. 132621 -0010WO01
[0102] In some aspects, the anti-EDDP antibody may comprise an HM381 anti-EDDP antibody. The HM381 anti-EDDP antibody may be an EDDP antibody available from Medix Biochemica. The HM381 anti-EDDP antibody may be conjugated to gold nanoparticles using passive conjugation as described herein.
[0103] In some aspects, the selection of the anti-EDDP antibody may depend on the specific assay configuration and performance characteristics desired. In some cases, different anti-EDDP antibodies may provide different binding characteristics and assay performance when paired with different EDDP:BSA conjugate test line reagents. In some cases, the anti-EDDP antibody may be selected based on reagent pair testing to identify combinations that provide suitable inhibition characteristics for quantitative EDDP detection.
[0104] In some aspects, the anti-EDDP antibody may be conjugated to 40 nm gold nanoparticles. The gold-labeled anti-EDDP antibody conjugate may be prepared using passive conjugation in one or more conjugation buffers as described herein. In some cases, the gold-labeled anti-EDDP antibody conjugate may be applied to the conjugate pad at an optical density of OD5, OD7.5, or OD10. In some cases, the gold-labeled anti-EDDP antibody conjugate may be applied to the conjugate pad at an optical density of OD7.5.
[0105] In some aspects, the lateral flow devices described herein may include a methadone test line comprising an immobilized methadone:BSA conjugate for detection of methadone in blood or plasma samples. The methadone:BSA conjugate may be striped onto the nitrocellulose membrane to form the methadone test line. In some cases, the methadone:BSA conjugate may be selected from one or more commercially available methadone:BSA conjugate reagents suitable for use in lateral flow immunoassay applications.
[0106] In some aspects, the methadone:BSA conjugate may comprise a DAG410 methadone:BSA conjugate. The DAG410 methadone:BSA conjugate may be a methadone [BSA] antigen available from Creative Diagnostics. The DAG410 methadone:BSA conjugate may be immobilized on the nitrocellulose membrane to form the methadone test line in the first detection zone.
[0107] In some aspects, the methadone:BSA conjugate may comprise an LA282 methadone:BSA conjugate. The LA282 methadone:BSA conjugate may be a methadone-BSA antigen available from Medix Biochemica. The LA282 methadone:BSA conjugate may be- 23 - 132621-0010W001 / 10715598.10Attorney Docket No. 132621 -0010WO01immobilized on the nitrocellulose membrane to form the methadone test line in the first detection zone.
[0108] In some aspects, the methadone:BSA conjugate may comprise an AGMTD-0302 methadone:BSA conjugate. The AGMTD-0302 methadone:BSA conjugate may be a methadone BSA antigen available from Fortis / Arista. The AGMTD-0302 methadone:BSA conjugate may be immobilized on the nitrocellulose membrane to form the methadone test line in the first detection zone.
[0109] In some aspects, the selection of the methadone:BSA conjugate may depend on the specific assay configuration and performance characteristics desired. In some cases, different methadone:BSA conjugates may provide different binding characteristics and assay performance when paired with different anti-methadone antibody conjugates. In some cases, the methadone:BSA conjugate may be selected based on reagent pair testing to identify combinations that provide suitable inhibition characteristics for quantitative methadone detection. In some cases, supplier-matched reagent pairs may provide improved assay performance compared to reagent pairs formed between different suppliers.
[0110] In some aspects, the methadone test line may be striped onto the nitrocellulose membrane at a concentration of approximately 0.25 mg / mL. The 0.25 mg / mL methadone test line concentration may provide a lower amount of methadone:BSA conjugate on the nitrocellulose membrane. In some cases, the 0.25 mg / mL methadone test line concentration may be used when a reduced amount of immobilized methadone:BSA conjugate is desired for a particular assay configuration.[oni] In some aspects, the methadone test line may be striped onto the nitrocellulose membrane at a concentration of approximately 0.5 mg / mL. The 0.5 mg / mL methadone test line concentration may provide a higher amount of methadone:BSA conjugate on the nitrocellulose membrane compared to the 0.25 mg / mL concentration. In some cases, the 0.5 mg / mL methadone test line concentration may be used for methadone quantification applications.
[0112] In some aspects, the selection of the methadone test line concentration may depend on the target assay range and the desired assay sensitivity. In some cases, different test line concentrations may provide different dose response characteristics when paired with different gold conjugate optical densities and spray rates. In some cases, the methadone test line- 24 - 132621-0010W001 / 10715598.10Attorney Docket No. 132621 -0010WO01concentration may be selected based on curve testing to identify combinations that provide suitable displacement characteristics over the required assay range.
[0113] In some aspects, the methadone test line may be striped onto the nitrocellulose membrane at a stripe rate of approximately 1 pL / cm. The 1 pL / cm stripe rate may provide a consistent and reproducible amount of methadone:BSA conjugate deposited on the nitrocellulose membrane. In some cases, the 1 pL / cm stripe rate may be used for both the methadone test line and the control line to provide consistency in the striping process.
[0114] In some aspects, the lateral flow devices described herein may include an EDDP test line comprising an immobilized EDDP:BSA conjugate for detection of EDDP in blood or plasma samples. The EDDP:BSA conjugate may be striped onto the nitrocellulose membrane to form the EDDP test line. In some cases, the EDDP:BSA conjugate may be selected from one or more commercially available EDDP:BSA conjugate reagents suitable for use in lateral flow immunoassay applications.
[0115] In some aspects, the EDDP:BSA conjugate may comprise a DAG-NS001 EDDP:BSA conjugate. The DAG-NS001 EDDP:BSA conjugate may be a methadone metabolite antigen conjugated to BSA available from Creative Diagnostics. The DAG-NS001 EDDP:BSA conjugate may be immobilized on the nitrocellulose membrane to form the EDDP test line in the detection zone.
[0116] In some aspects, the EDDP:BSA conjugate may comprise an LA279 EDDP:BSA conjugate. The LA279 EDDP:BSA conjugate may be an EDDP -BSA antigen available from Medix Biochemica. The LA279 EDDP:BSA conjugate may be immobilized on the nitrocellulose membrane to form the EDDP test line in the detection zone.
[0117] In some aspects, the selection of the EDDP:BSA conjugate may depend on the specific assay configuration and performance characteristics desired. In some cases, different EDDP:BSA conjugates may provide different binding characteristics and assay performance when paired with different anti-EDDP antibody conjugates. In some cases, the EDDP:BSA conjugate may be selected based on reagent pair testing to identify combinations that provide suitable inhibition characteristics for quantitative EDDP detection.
[0118] In some aspects, the EDDP test line may be striped onto the nitrocellulose membrane at a concentration of approximately 0.125 mg / mL. The 0.125 mg / mL EDDP test line concentration may provide a lower amount of EDDP:BSA conjugate on the nitrocellulose - 25 - 132621-0010W001 / 10715598.10Attorney Docket No. 132621 -0010WO01membrane. In some cases, the 0.125 mg / mL EDDP test line concentration may be used in combination with a higher conjugate spray rate to shift the assay range toward lower analyte concentrations.
[0119] In some aspects, the EDDP test line may be striped onto the nitrocellulose membrane at a concentration of approximately 0.25 mg / mL. The 0.25 mg / mL EDDP test line concentration may provide a moderate amount of EDDP:BSA conjugate on the nitrocellulose membrane. In some cases, the 0.25 mg / mL EDDP test line concentration may be used for EDDP quantification applications.
[0120] In some aspects, the EDDP test line may be striped onto the nitrocellulose membrane at a concentration of approximately 0.5 mg / mL. The 0.5 mg / mL EDDP test line concentration may provide a higher amount of EDDP:BSA conjugate on the nitrocellulose membrane compared to the 0.125 mg / mL and 0.25 mg / mL concentrations. In some cases, the 0.5 mg / mL EDDP test line concentration may be used when a higher amount of immobilized EDDP :B SA conjugate is desired for a particular assay configuration.
[0121] In some aspects, the selection of the EDDP test line concentration may depend on the target assay range and the desired assay sensitivity. In some cases, different test line concentrations may provide different dose response characteristics when paired with different gold conjugate optical densities and spray rates. In some cases, the EDDP test line concentration may be selected based on curve testing to identify combinations that provide suitable displacement characteristics over the required assay range.
[0122] In some aspects, the EDDP test line may be striped onto the nitrocellulose membrane at a stripe rate of approximately 1 pL / cm. The 1 pL / cm stripe rate may provide a consistent and reproducible amount of EDDP:BSA conjugate deposited on the nitrocellulose membrane. In some cases, the 1 pL / cm stripe rate may be used for both the EDDP test line and the control line to provide consistency in the striping process.
[0123] In some aspects, the lateral flow devices described herein may include a control-line zone configured to provide a control signal indicating proper assay function. The control-line zone may be positioned on the nitrocellulose membrane downstream of the detection zone or detection zones. In some cases, the control-line zone may capture labeled antibody that has flowed through the detection zone or detection zones, providing confirmation that the sample has flowed properly through the lateral flow device.- 26 - 132621-0010W001 / 10715598.10Attorney Docket No. 132621 -0010WO01
[0124] In some aspects, the control-line zone may comprise a goat anti-mouse (GAM) antibody. The GAM antibody may be configured to capture mouse monoclonal antibodies that have flowed through the detection zones. In some cases, the GAM antibody may capture gold-labeled anti-methadone antibody that is bound to methadone present in the sample. In some cases, the GAM antibody may capture gold-labeled anti-EDDP antibody that is bound to EDDP present in the sample. The captured labeled antibody may emit a detectable control signal at the control-line zone.
[0125] In some aspects, the GAM antibody may be striped onto the nitrocellulose membrane at a concentration of approximately 0.5 mg / mL. The 0.5 mg / mL GAM concentration may provide a suitable amount of capture antibody for generating a visible control signal. In some cases, the GAM antibody may be striped onto the nitrocellulose membrane at a stripe rate of approximately 1 pL / cm. The 1 pL / cm stripe rate may provide consistency with the stripe rate used for the test lines on the nitrocellulose membrane.
[0126] In some aspects, the lateral flow devices may include an independent control line. An independent control line may be configured such that the control-line result is not affected by the test-line result. In some cases, an independent control line may be used in multiplex lateral flow devices configured to quantify both methadone and EDDP in a single sample.
[0127] In some aspects, the independent control line may comprise a chicken IgY control line. Chicken IgY may serve as an alternative control line reagent to the GAM antibody. In some cases, the chicken IgY control line may be used with a corresponding gold-labeled chicken IgY conjugate that flows through the lateral flow device independently of the gold-labeled anti-methadone antibody and gold-labeled anti-EDDP antibody. The chicken IgY control line may provide a control signal that is independent of the analyte concentrations in the sample.
[0128] In some aspects, the selection of the control line configuration may depend on the specific assay format and performance characteristics desired. In some cases, the GAM control line may be used for lateral flow devices configured to quantify a single analyte. In some cases, the independent control line may be used for multiplex lateral flow devices to provide a control signal that is not affected by the binding of labeled antibodies at the test lines.
[0129] In some aspects, the lateral flow test-strip devices described herein may include a sample pad configured to receive a blood or plasma sample. The sample pad may be positioned at an upstream end of the lateral flow device and may be coupled to the conjugate pad. In some- 27 - 132621-0010W001 / 10715598.10Attorney Docket No. 132621 -0010WO01cases, the sample pad may be configured to receive whole blood samples and separate cellular components from plasma before the sample flows through the conjugate pad and onto the nitrocellulose membrane.
[0130] In some aspects, the sample pad may comprise an MD1 blood separation pad. The MD1 blood separation pad may be configured to receive whole blood samples and separate red blood cells and other cellular components from plasma. In some cases, the MD1 blood separation pad may allow plasma to flow through to the conjugate pad while retaining cellular components. The MD1 blood separation pad may facilitate the use of fingerstick capillary blood samples in the lateral flow device.
[0131] In some aspects, the sample pad may comprise an FR1 sample pad. The FR1 sample pad may have a length of approximately 15 mm. In some cases, the FR1 sample pad may be configured to receive a pre-mixed sample comprising a blood or plasma sample that has been contacted with a pre-mix running buffer prior to loading onto the lateral flow device. The 15 mm length of the FR1 sample pad may provide sufficient capacity to receive the pre-mixed sample volume.
[0132] In some aspects, the lateral flow test-strip devices described herein may include an absorbent pad configured to wick fluid through the device and collect excess sample. The absorbent pad may be positioned at a downstream end of the lateral flow device, downstream of the nitrocellulose membrane and the detection zones. The absorbent pad may provide capillary action to draw the sample through the flow path of the lateral flow device.
[0133] In some aspects, the absorbent pad may comprise a grade 222 absorbent pad. The grade 222 absorbent pad may have a length of approximately 20 mm. In some cases, the grade 222 absorbent pad may be configured to absorb excess fluid after the sample has flowed through the detection zones on the nitrocellulose membrane. The 20 mm length of the grade 222 absorbent pad may provide sufficient absorptive capacity for the sample volumes used in the lateral flow device.
[0134] In some aspects, the lateral flow test-strip devices described herein may include a backing card configured to provide structural support for the lateral flow device components. The backing card may support the sample pad, the conjugate pad, the nitrocellulose membrane, and the absorbent pad in a sequential arrangement along the flow path. In some cases, the- 28 - 132621-0010W001 / 10715598.10Attorney Docket No. 132621 -0010WO01backing card may comprise an adhesive backing card onto which the lateral flow device components are mounted.
[0135] In some aspects, the backing card may have a length of approximately 60 mm. The 60 mm backing card may be configured to accommodate the sample pad, the conjugate pad, the nitrocellulose membrane, and the absorbent pad components of the lateral flow test-strip device. In some cases, the 60 mm backing card length may provide sufficient length to support the overlapping arrangement of the lateral flow device components along the flow path.
[0136] In some aspects, the lateral flow test-strip devices described herein may be housed within a device housing. The device housing may be configured to enclose and protect the lateral flow test-strip device components. In some cases, the device housing may include a sample application port configured to allow application of a sample to the sample pad. In some cases, the device housing may include one or more viewing windows configured to allow visualization of the detection zones and control-line zone on the nitrocellulose membrane.
[0137] In some aspects, the device housing may have a length of approximately 60 mm. The 60 mm device housing may be configured to accommodate the lateral flow test-strip device mounted on the 60 mm backing card. In some cases, the device housing may be configured for insertion into a reader for detection and quantification of signal intensity from the detection zones. The device housing may protect the lateral flow test-strip device from contamination and physical damage during handling and use.
[0138] In some aspects, the lateral flow devices described herein may be configured for use with various sample types and matrices. The lateral flow devices may be compatible with whole blood samples, plasma samples, and serum samples. The selection of sample type may depend on the clinical setting and sample collection method available.
[0139] In some aspects, the lateral flow devices may be configured for use with fingerstick blood samples. A lancet may be used to draw out a drop of capillary blood from the fingertip of a subject. The capillary blood sample may be collected directly from the fingerstip following the lancet puncture. In some cases, the capillary blood sample may be mixed with a fixed volume of pre-mix running buffer to form a pre-mixed sample prior to loading onto the lateral flow device. The pre-mixed sample mixture may be transferred to the lateral flow device, where the sample may be brought into contact with the assay either directly or through capillary action.- 29 - 132621-0010W001 / 10715598.10Attomey Docket No. 132621 -0010WO01
[0140] In some aspects, the lateral flow devices may include a blood separation sample pad configured to receive whole blood samples. The blood separation sample pad may separate cellular components, including red blood cells, from plasma before the sample flows through the conjugate pad and onto the nitrocellulose membrane. In some cases, the blood separation sample pad may comprise an MD1 blood separation pad. The MD1 blood separation pad may allow plasma to flow through to the conjugate pad while retaining cellular components. The blood separation sample pad may facilitate the use of fingerstick capillary blood samples in the lateral flow device.
[0141] In some aspects, sample volumes may be selected based on the relationship between plasma volume and whole blood volume. In some cases, a plasma sample volume of 15 pL may represent approximately 30 pL of whole blood. In some cases, a plasma sample volume of 25 pL may represent approximately 50 pL of whole blood. The sample volume may be diluted in the pre-mix running buffer to a total assay volume of approximately 100 pL.
[0142] In some aspects, the lateral flow devices may be configured for use with plasma samples. In some cases, a plasma sample volume of approximately 5 pL may be used for methadone quantification. In some cases, a plasma sample volume of approximately 10 pL may be used for EDDP quantification. The plasma sample may be diluted in the pre-mix running buffer prior to loading onto the lateral flow device.
[0143] In some aspects, the lateral flow devices may be configured for use with serum samples as an alternative to plasma samples. Serum may serve as an alternative sample matrix to plasma for methadone and EDDP quantification. In some cases, the lateral flow devices may exhibit minimal matrix effect between plasma and serum samples. The minimal matrix effect may result in similar curve performance between plasma and serum matrices. In some cases, the curve shape, curve position, and assay performance may be similar between plasma and serum samples. The compatibility with both plasma and serum sample matrices may provide flexibility in sample collection and processing methods for the lateral flow devices.
[0144] In some aspects, the lateral flow devices described herein may be configured for use with various sample volumes and buffer configurations. The sample volume and buffer volume may be selected based on the target analyte and the desired assay range. In some cases, the total assay volume may be maintained at approximately 100 pL across different sample volume configurations.- 30 - 132621-0010W001 / 10715598.10Attorney Docket No. 132621 -0010WO01
[0145] In some aspects, a methadone quantification configuration may use a plasma or serum sample volume of approximately 5 pL. The 5 pL plasma or serum sample may be mixed with approximately 95 pL of pre-mix running buffer to form a pre-mixed sample with a total volume of approximately 100 pL. The 5 pL sample volume may provide suitable sensitivity for methadone quantification over the assay range of approximately 75 ng / mL to approximately 1600 ng / mL.
[0146] In some aspects, an EDDP quantification configuration may use a plasma or serum sample volume of approximately 10 pL. The 10 pL plasma or serum sample may be mixed with approximately 90 pL of pre-mix running buffer to form a pre-mixed sample with a total volume of approximately 100 pL. The 10 pL sample volume may provide suitable sensitivity for EDDP quantification over the assay range of approximately 5 ng / mL to approximately 500 ng / mL. In some cases, the increased sample volume for EDDP quantification compared to methadone quantification may shift the assay range toward lower analyte concentrations.
[0147] In some aspects, a chase system may be used as an alternative to the pre-mix running buffer system. In a chase system configuration, the blood or plasma sample may be loaded directly onto the lateral flow device, followed by application of a chase buffer. The chase buffer may flow through the lateral flow device and carry the sample through the flow path to the detection zones.
[0148] In some aspects, a 15 pL chase system configuration may be used. The 15 pL chase system may use a sample volume of approximately 15 pL followed by a chase buffer volume of approximately 85 pL to maintain a total assay volume of approximately 100 pL. The 15 pL sample volume may represent approximately 30 pL of whole blood when plasma is used as the sample matrix.
[0149] In some aspects, a 25 pL chase system configuration may be used as an alternative to the 15 pL chase system. The 25 pL chase system may use a sample volume of approximately 25 pL followed by a chase buffer volume of approximately 75 pL to maintain a total assay volume of approximately 100 pL. The 25 pL sample volume may represent approximately 50 pL of whole blood when plasma is used as the sample matrix.
[0150] In some aspects, the pre-mix running buffer system may provide improved flow characteristics compared to the chase system. The pre-mix running buffer system may reduce- 31 - 132621-0010W001 / 10715598.10Attomey Docket No. 132621 -0010WO01hotspots and streaking on the nitrocellulose membrane. In some cases, the pre-mix running buffer system may improve consistency between repetitions compared to the chase system.
[0151] In some aspects, the test systems described herein may be provided as a kit for point-of-care quantification of methadone and EDDP. The kit may comprise a lateral flow test strip device, a pre-mix running buffer, and instructions for use. In some cases, the kit may further comprise a reader comprising a light source and a detector, and a data analyzer configured to convert detected signal intensity to analyte concentration based on a dose response curve. In some cases, the kit may further comprise a lancet for obtaining a capillary blood sample from a fingertip of a subj ect.
[0152] In some aspects, the kit may include instructions for use. The instructions for use may describe the procedure for collecting a blood or plasma sample, contacting the sample with the pre-mix running buffer to form a pre-mixed sample, loading the pre-mixed sample onto the lateral flow test strip device, and interpreting the results. In some cases, the instructions for use may describe the sample volume, buffer volume, and assay run time for the specific kit configuration.
[0153] In some aspects, the blood or plasma sample may be loaded directly onto the lateral flow device without prior mixing with a buffer. In a direct loading configuration, the sample may be applied directly to the sample pad of the lateral flow device. The lateral flow device may include flow path chemistry dispensed upstream of the detection zone that is configured to facilitate sample flow and reduce non-specific binding. In some cases, a chase buffer may be applied to the lateral flow device after the sample has been loaded to facilitate flow of the sample through the device.
[0154] In some aspects, the selection of sample volume and buffer configuration may depend on the specific assay requirements and the target analyte. In some cases, different sample volumes may be used for methadone and EDDP detection in a multiplex lateral flow device. In a multiplex configuration, the methadone assay may use a 5 pL plasma or serum sample mixed with 95 pL of pre-mix running buffer, and the EDDP assay may use a 10 pL plasma or serum sample mixed with 90 pL of pre-mix running buffer, with each configuration maintaining a total assay volume of approximately 100 pL.
[0155] In some aspects, the lateral flow devices described herein may be configured for various assay run time configurations. The assay run time may refer to the time period between- 32 - 132621-0010W001 / 10715598.10Attorney Docket No. 132621 -0010WO01loading the pre-mixed sample onto the lateral flow device and detecting the signal intensity from the detection zones. The selection of assay run time may depend on the specific assay requirements and the clinical setting in which the lateral flow device is used.
[0156] In some aspects, the lateral flow devices may be configured for a standard assay run time of approximately 30 minutes. The 30 minute run time may allow sufficient time for the sample to flow through the lateral flow device and for the labeled antibody conjugates to bind at the detection zones. In some cases, the 30 minute run time may provide suitable signal development for quantification of methadone and EDDP concentrations in blood or plasma samples.
[0157] In some aspects, the lateral flow devices may be configured for an assay run time of 25 minutes or less. The 25 minute or less run time may provide a reduced time to result compared to the standard 30 minute run time. In some cases, the 25 minute or less run time may be used when a faster turnaround time is desired in the clinical setting.
[0158] In some aspects, the lateral flow devices may be configured for an assay run time of 20 minutes or less. The 20 minute or less run time may provide a further reduced time to result compared to the 25 minute or less run time. In some cases, the 20 minute or less run time may be used in point-of-care settings where rapid results are desired.
[0159] In some aspects, the lateral flow devices may be configured for an assay run time of 15 minutes or less. The 15 minute or less run time may provide the shortest time to result among the assay run time configurations described herein. In some cases, the 15 minute or less run time may be used in clinical settings where rapid turnaround is desired for timely clinical decisionmaking.
[0160] In some aspects, the selection of assay run time may depend on the specific lateral flow device configuration and the target analyte. In some cases, the assay run time may be selected based on the signal development characteristics of the specific reagent combinations used in the lateral flow device. In some cases, different assay run times may provide different signal intensities and assay performance characteristics for methadone and EDDP quantification.
[0161] In some aspects, the lateral flow devices described herein may be configured for use with a reader for signal detection and quantification. The reader may comprise a light source and a detector configured to measure signal intensity from the detection zones on the lateral flow- 33 - 132621-0010W001 / 10715598.10Attomey Docket No. 132621 -0010WO01device. A data analyzer may be configured to process the detected signal intensity and convert the signal intensity to analyte concentration based on a dose response curve.
[0162] In some aspects, the lateral flow test-strip device may be inserted into a reader for signal detection. The reader may comprise an Axxin reader. The Axxin reader may be configured to detect signal intensity from the test lines and control lines on the nitrocellulose membrane. In some cases, the Axxin reader may be used for quantification of methadone and EDDP concentrations in blood or plasma samples.
[0163] In some aspects, the reader may comprise an iPeak reader. The iPeak reader may be configured to detect signal intensity from the test lines and control lines on the nitrocellulose membrane. In some cases, the iPeak reader may generate an iPeak Area Score corresponding to the signal intensity at each detection zone. The iPeak Area Score may be used to quantify analyte concentration based on a dose response curve. In some cases, signal intensities may be quantified both visually and using the iPeak reader.
[0164] In some aspects, the reader may be configured with test line and control line (T / C line) discrimination capability. The T / C line discrimination capability may allow the reader to distinguish between the test band and the control band on the lateral flow device. The reader may collect data from each band's intensity, with the intensity correlating with the quantity or number of immobilized conjugate molecules in each band. The reader may process the data collected from reading each of the bands separately.
[0165] In some aspects, the reader may be configured to perform control band validation to determine whether the assay performed properly. The reader may process information regarding the intensity of the control band to determine whether the assay performed properly. In some cases, the control band intensity may indicate that the sample has flowed properly through the lateral flow device and that the assay reagents are functioning as expected. The control band validation may provide confirmation that the test results are valid before reporting analyte concentrations.
[0166] In some aspects, the reader may process information regarding the intensity of the test band to determine a quantity of the target analytes methadone and EDDP present in the tested sample. The reader may convert the measured detected signal intensity to an analyte concentration based on a dose response curve. In some cases, the reader may be programmed to display one or more results based on the data collected from the detection zones.- 34 - 132621-0010W001 / 10715598.10Attorney Docket No. 132621 -0010WO01
[0167] In some aspects, the reader may be programmed to display whether the assay performed properly. In some cases, the reader may display whether or not methadone and EDDP was present in the sample if the assay performed properly. In some cases, the reader may display the quantity and concentration of methadone and EDDP in the sample based on a dose response curve if the target analytes were present. One or more of the displayed results may be associated with a clinical condition.
[0168] In some aspects, the reader may be configured for use with multiplex lateral flow devices that detect the concentration of both methadone and EDDP. The reader may be programmed to display whether the assay performed properly, whether or not methadone was present in the sample, the quantity of methadone in the sample if methadone was present, whether or not EDDP was present in the sample, the quantity of EDDP in the sample if EDDP was present, and the concentration ratio of methadone to EDDP in the sample based on dose response curves. The concentration ratio results may be used to calculate the methadone to metabolite ratio (MMR) of methadone to EDDP.
[0169] In some aspects, the data analyzer may be configured to analyze reader data using a four-parameter logistic (4PL) curve fit. The 4PL curve fit may be used to generate a dose response curve from standard concentrations. In some cases, values may be interpolated from the 4PL curve to determine analyte concentration from the measured signal intensity. The 4PL curve fit analysis may be used to assess accuracy and precision of the quantification results.
[0170] In some aspects, the lateral flow test-strip device may be inserted into the reader, and the pre-mixed sample may be loaded onto the lateral flow device. The lateral flow test-strip device may process the sample, and the reader may determine the methadone and EDDP concentrations. The results may be displayed on a connected user interface. In some cases, the results may be available within the assay run time of approximately 15 minutes, 20 minutes, 25 minutes, or 30 minutes depending on the assay configuration.
[0171] In some aspects, the data analyzer may be configured to analyze reader data using a four-parameter logistic (4PL) curve fit. The 4PL curve fit may be used to generate a dose response curve from standard concentrations of known analyte levels. The 4PL curve fit may model the relationship between signal intensity and analyte concentration as a sigmoidal function. In some cases, the 4PL curve fit may be represented by the equation:- 35 - 132621-0010W001 / 10715598.10Attomey Docket No. 132621 -0010WO01
[0172] where y represents the signal intensity, x represents the analyte concentration, a represents the minimum asymptote, d represents the maximum asymptote, c represents the inflection point corresponding to the concentration at which the response is halfway between the minimum and maximum asymptotes, and b represents the Hill slope describing the steepness of the curve.
[0173] In some aspects, the dose response curve may be generated by measuring signal intensities from a series of standard samples containing known concentrations of methadone or EDDP. The standard samples may span the full assay range for the target analyte. In some cases, the standard samples for methadone quantification may span a concentration range of approximately 75 ng / mL to approximately 1600 ng / mL. In some cases, the standard samples for EDDP quantification may span a concentration range of approximately 5 ng / mL to approximately 500 ng / mL.
[0174] In some aspects, multiple replicates of each standard concentration may be measured to generate the dose response curve. In some cases, five replicates of each standard concentration may be measured. In some cases, three replicates of each standard concentration may be measured. The use of multiple replicates may improve the statistical reliability of the dose response curve.
[0175] In some aspects, analyte concentrations in unknown samples may be determined by interpolating values from the dose response curve. The data analyzer may measure the signal intensity from an unknown sample and determine the corresponding analyte concentration by interpolating from the 4PL curve fit. In some cases, the interpolation may involve solving the 4PL equation for the concentration value that corresponds to the measured signal intensity.
[0176] In some aspects, the accuracy of the quantification may be assessed using percent recovery values. Percent recovery may be calculated as the ratio of the measured concentration to the nominal concentration, expressed as a percentage. In some cases, percent recovery values may range from approximately 90% to approximately 110% across the assay range. In some cases, percent recovery values may range from approximately 96% to approximately 109% for methadone quantification. In some cases, percent recovery values may range from approximately 97% to approximately 104% for EDDP quantification.
[0177] In some aspects, the precision of the quantification may be assessed using the coefficient of variation (CV). The coefficient of variation may be calculated as the ratio of the- 36 - 132621-0010W001 / 10715598.10Attomey Docket No. 132621 -0010WO01standard deviation to the mean of replicate measurements, expressed as a percentage. In some cases, the CV may be less than 30%, 20%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, or 5%. In some cases, CV values may range from approximately 5.9% to approximately 10.6% across the assay range for EDDP quantification. In some cases, CV values may range from approximately 10% to approximately 34% across the assay range for methadone quantification.
[0178] In some aspects, the accuracy and precision of the lateral flow devices may be validated using patient samples with known analyte concentrations. Patient samples with characterization data may be tested on the lateral flow devices, and the measured concentrations may be compared to the nominal concentrations. The percent recovery and CV values from patient sample testing may provide an assessment of the accuracy and precision of the lateral flow devices in clinical sample matrices.
[0179] In some aspects, the data analyzer may calculate the mean, standard deviation, percent CV, and percent recovery for each concentration level tested. The mean may be calculated as the average of the replicate measurements. The standard deviation may be calculated as a measure of the dispersion of the replicate measurements around the mean. The percent CV may be calculated by dividing the standard deviation by the mean and multiplying by 100. The percent recovery may be calculated by dividing the mean measured concentration by the nominal concentration and multiplying by 100.
[0180] In some aspects, the dose response curve may exhibit a characteristic sigmoidal inhibition profile. In an inhibition lateral flow format, higher analyte concentrations in the sample may result in lower signal intensity at the test line. The 4PL curve fit may model the inverse relationship between analyte concentration and signal intensity in the inhibition format assay. Referring to FIG. 4, a dose-response curve for the methadone lateral flow assay illustrates the iPeak Area Score as a function of methadone concentration, demonstrating the sigmoidal inhibition profile. Referring to FIG. 5, a dose-response curve for the EDDP lateral flow assay illustrates the iPeak Area Score as a function of EDDP concentration, demonstrating a similar sigmoidal inhibition profile.
[0181] In some aspects, the reader may be configured to display various output options based on the data collected from the lateral flow device. The reader may be programmed to provide assay validity display, presence or absence display, concentration display, and ratio display outputs. The display outputs may be presented on a connected user interface.- 37 - 132621-0010W001 / 10715598.10Attorney Docket No. 132621 -0010WO01
[0182] In some aspects, the reader may be configured to display an assay validity output. The assay validity output may indicate whether the assay performed properly. The reader may process information regarding the intensity of the control band to determine whether the assay performed properly. In some cases, the control band intensity may indicate that the sample has flowed properly through the lateral flow device and that the assay reagents are functioning as expected. The assay validity display may provide confirmation that the test results are valid before reporting analyte concentrations.
[0183] In some aspects, the reader may be configured to display a presence or absence output for methadone. The presence or absence output may indicate whether or not methadone was detected in the sample. In some cases, the reader may display the presence or absence output for methadone when the assay has performed properly as indicated by the assay validity output.
[0184] In some aspects, the reader may be configured to display a presence or absence output for EDDP. The presence or absence output may indicate whether or not EDDP was detected in the sample. In some cases, the reader may display the presence or absence output for EDDP when the assay has performed properly as indicated by the assay validity output.
[0185] In some aspects, the reader may be configured to display a concentration output for methadone. The concentration output may indicate the quantity and concentration of methadone in the sample based on a dose response curve. In some cases, the reader may display the concentration output for methadone when methadone was detected in the sample. The methadone concentration output may be displayed in units of ng / mL.
[0186] In some aspects, the reader may be configured to display a concentration output for EDDP. The concentration output may indicate the quantity and concentration of EDDP in the sample based on a dose response curve. In some cases, the reader may display the concentration output for EDDP when EDDP was detected in the sample. The EDDP concentration output may be displayed in units of ng / mL.
[0187] In some aspects, the reader may be configured for use with multiplex lateral flow devices that detect the concentration of both methadone and EDDP. The reader may be programmed to display whether the assay performed properly, whether or not methadone was present in the sample, the quantity of methadone in the sample if methadone was present, whether or not EDDP was present in the sample, and the quantity of EDDP in the sample if EDDP was present.- 38 - 132621-0010W001 / 10715598.10Attomey Docket No. 132621 -0010WO01
[0188] In some aspects, the reader may be configured to display a ratio output for multiplex lateral flow devices. The ratio output may indicate the concentration ratio of methadone to EDDP in the sample based on dose response curves. The concentration ratio results may be used to calculate the methadone to metabolite ratio (MMR) of methadone to EDDP. The MMR may represent the net metabolism and may be used to assign a specific metabolic category to a patient.
[0189] In some aspects, the MMR values may be divided into metabolic categories. The metabolic categories may include ultra-rapid (URM), extensive (EM), intermediate (IM), and ultra-slow (USM) categories. In some cases, underdosing may occur in the URM category. In some cases, excessive dosing may occur in the IM and USM categories. The assignment of a patient to a specific metabolic category based on the MMR may assist clinicians in making dosing decisions.
[0190] In some aspects, one or more of the displayed results may be associated with a clinical condition. The clinical condition association may provide information to assist clinicians in managing the dose of methadone prescribed for patients with opioid use disorder. In some cases, the displayed results may provide point-of-care objective feedback on a patient's methadone dosing based on pharmacokinetic information.
[0191] In some aspects, the reader may be configured to record numerical data for each patient. The recorded data may include methadone concentrations, EDDP concentrations, and MMR values over time. In some cases, the reader may perform linear regression calculations on the recorded data. The reader may deliver a day-by-day evaluation of the patient's assigned metabolic category based on the recorded data and calculations.
[0192] In some aspects, the displayed results may be combined with other clinical information to determine personalized dose adjustments. The other clinical information may include information on continued use of illicit substances, current medications, cravings, withdrawal status, and level of opioid tolerance. In some cases, the combination of pharmacokinetic data from the lateral flow device with other clinical information may support personalized dose adjustments for patients in the induction or maintenance stages of medication assisted treatment.
[0193] In some aspects, the reader may be configured to track changes in the MMR over time. The MMR may vary during the initial time period after methadone treatment has been started. In some cases, the MMR values may level off and approach a limit value after- 39 - 132621-0010W001 / 10715598.10Attorney Docket No. 132621 -0010WO01approximately 10 days. Following the MMR value as the MMR approaches a steady state number may provide initial dosing feedback and assistance for the clinician. In some cases, the MMR test may be applied at least every other day during the first 10 days of induction, followed by once a month for the next three months and then quarterly after that.
[0194] In some aspects, the lateral flow devices described herein may exhibit assay performance characteristics suitable for quantitative measurement of methadone and EDDP in blood or plasma samples. The assay performance characteristics may include accuracy characteristics and precision characteristics that support clinical decision-making in point-of-care settings.
[0195] In some aspects, the accuracy of the methadone quantification may be assessed using percent recovery values. Percent recovery may be calculated as the ratio of the measured concentration to the nominal concentration, expressed as a percentage. In some cases, the methadone assay may exhibit percent recovery values ranging from approximately 90% to approximately 95% across the assay range. In some cases, the methadone assay may exhibit percent recovery values ranging from approximately 90.5% to approximately 96.9% across the concentration range of 75 ng / mL to 1600 ng / mL. In some cases, the methadone assay may exhibit percent recovery values of approximately 90.5% at 500 ng / mL, approximately 91.2% at 800 ng / mL, approximately 92.0% at 200 ng / mL, approximately 93.6% at 1600 ng / mL, approximately 94.4% at 1800 ng / mL, approximately 95.3% at 1200 ng / mL, and approximately 96.9% at 75 ng / mL.
[0196] In some aspects, the accuracy of the EDDP quantification may be assessed using percent recovery values. In some cases, the EDDP assay may exhibit percent recovery values ranging from approximately 88% to approximately 110% across the assay range. In some cases, the EDDP assay may exhibit percent recovery values ranging from approximately 88.9% to approximately 109.9% across the concentration range of 25 ng / mL to 600 ng / mL. In some cases, the EDDP assay may exhibit percent recovery values of approximately 88.9% at 600 ng / mL, approximately 93.9% at 500 ng / mL, approximately 96.5% at 50 ng / mL, approximately 102.1% at 25 ng / mL, approximately 106.8% at 100 ng / mL, and approximately 109.9% at 250 ng / mL.
[0197] In some aspects, the precision of the methadone quantification may be assessed using the coefficient of variation (CV). The coefficient of variation may be calculated as the ratio of the standard deviation to the mean of replicate measurements, expressed as a percentage. In some cases, the methadone assay may exhibit CV values of less than 17% for concentrations - 40 - 132621-0010W001 / 10715598.10Attorney Docket No. 132621 -0010WO01above 50 ng / mL. In some cases, the methadone assay may exhibit CV values ranging from approximately 7.8% to approximately 16.6% across the concentration range of 75 ng / mL to 1800 ng / mL. In some cases, the methadone assay may exhibit CV values of approximately 7.8% at 1800 ng / mL, approximately 9.1% at 1600 ng / mL, approximately 11.5% at 500 ng / mL, approximately 12.4% at 200 ng / mL, approximately 12.8% at 75 ng / mL, approximately 16.1% at 800 ng / mL, and approximately 16.6% at 1200 ng / mL.
[0198] In some aspects, the precision of the EDDP quantification may be assessed using the coefficient of variation. In some cases, the EDDP assay may exhibit CV values of less than 10% for concentrations above 50 ng / mL. In some cases, the EDDP assay may exhibit CV values ranging from approximately 5.8% to approximately 12.5% across the concentration range of 50 ng / mL to 600 ng / mL. In some cases, the EDDP assay may exhibit CV values of approximately 5.8% at 600 ng / mL, approximately 6.9% at 50 ng / mL, approximately 7.1% at 100 ng / mL, approximately 7.5% at 500 ng / mL, approximately 7.9% at 25 ng / mL, approximately 9.4% at 250 ng / mL, and approximately 12.5% at 100 ng / mL in serum matrix.
[0199] In some aspects, the lateral flow devices may exhibit minimal matrix effect between plasma and serum samples. The minimal matrix effect may result in similar curve performance between plasma and serum matrices. In some cases, the curve shape, curve position, and assay performance may be similar between plasma and serum samples for both methadone and EDDP quantification. Referring to FIG. 6, a comparison of dose-response curves for the methadone lateral flow assay in plasma and serum matrices illustrates the minimal matrix effect between the two sample types. Referring to FIG. 7, a comparison of dose-response curves for the EDDP lateral flow assay in plasma and serum matrices illustrates a similar minimal matrix effect.
[0200] In some aspects, the accuracy and precision of the lateral flow devices may be validated using patient samples with known analyte concentrations. Patient samples with characterization data may be tested on the lateral flow devices, and the measured concentrations may be compared to the nominal concentrations. The percent recovery and CV values from patient sample testing may provide an assessment of the accuracy and precision of the lateral flow devices in clinical sample matrices.
[0201] In some aspects, the lateral flow devices described herein may be configured as multiplex lateral flow devices for simultaneous quantification of both methadone and EDDP in a single blood or plasma sample. A multiplex lateral flow device may include both a methadone test line and an EDDP test line on the same nitrocellulose membrane. The multiplex - 41 - 132621-0010W001 / 10715598.10Attorney Docket No. 132621 -0010WO01configuration may allow for determination of both methadone concentration and EDDP concentration from a single sample, which may facilitate calculation of the methadone to metabolite ratio (MMR).
[0202] In some aspects, the multiplex lateral flow device may include a first detection zone comprising an immobilized methadone:BSA conjugate and a second detection zone comprising an immobilized EDDP:BSA conjugate. The first detection zone and the second detection zone may be positioned sequentially along the flow path on the nitrocellulose membrane. In some cases, the first detection zone and the second detection zone may be positioned upstream of a control-line zone.
[0203] In some aspects, the multiplex lateral flow device may be configured with the EDDP test line positioned first along the flow path, upstream of the methadone test line. In an EDDP T-line first configuration, the EDDP test line may be positioned closer to the sample receiving zone than the methadone test line. The sample may flow through the EDDP test line before flowing through the methadone test line. In some cases, the EDDP T-line first configuration may provide improved displacement characteristics at lower analyte concentrations.
[0204] In some aspects, the multiplex lateral flow device may be configured with the methadone test line positioned first along the flow path, upstream of the EDDP test line. In a methadone T-line first configuration, the methadone test line may be positioned closer to the sample receiving zone than the EDDP test line. The sample may flow through the methadone test line before flowing through the EDDP test line.
[0205] In some aspects, the curve shapes for both methadone and EDDP may be similar regardless of the order of the test lines on the nitrocellulose membrane. In some cases, the selection of test line order may depend on the specific assay requirements and the desired displacement characteristics at different concentration ranges.
[0206] In some aspects, the multiplex lateral flow device may include a mixed conjugate pad configuration. In a mixed conjugate pad configuration, both the gold-labeled anti-methadone antibody conjugate and the gold-labeled anti-EDDP antibody conjugate may be combined on a single conjugate pad. The mixed conjugate pad may release both labeled antibody conjugates when a sample is applied to the lateral flow device. In some cases, the mixed conjugate pad configuration may allow for simultaneous detection of both methadone and EDDP using a single conjugate pad component.- 42 - 132621-0010W001 / 10715598.10Attorney Docket No. 132621 -0010WO01
[0207] In some aspects, the mixed conjugate pad may comprise an Ahlstrom 8980 conjugate pad pretreated with a PPI pretreatment buffer. The gold-labeled anti -methadone antibody conjugate may be applied to the mixed conjugate pad at an optical density of OD7.5. The gold-labeled anti-EDDP antibody conjugate may be applied to the mixed conjugate pad at an optical density of OD7.5. In some cases, the use of the same optical density for both antibody conjugates may provide consistency between the methadone and EDDP assays in the multiplex configuration.
[0208] In some aspects, the gold-labeled anti-methadone antibody conjugate may be applied to the mixed conjugate pad at a spray rate of approximately 10 pL / cm. The gold-labeled anti-EDDP antibody conjugate may be applied to the mixed conjugate pad at a spray rate of approximately 10 pL / cm. In some cases, the gold-labeled anti-EDDP antibody conjugate may be applied at a spray rate of approximately 12 pL / cm.
[0209] In some aspects, the multiplex lateral flow device may include a methadone test line comprising an AGMTD-0302 methadone:BSA conjugate at a concentration of approximately 0.25 mg / mL to approximately 0.5 mg / mL. The multiplex lateral flow device may include an EDDP test line comprising a DAG-NS001 EDDP:BSA conjugate at a concentration of approximately 0.25 mg / mL to approximately 0.5 mg / mL. The methadone test line and the EDDP test line may be striped onto the nitrocellulose membrane at a stripe rate of approximately 1 pL / cm.
[0210] In some aspects, the multiplex lateral flow device may include a control-line zone comprising a goat anti-mouse (GAM) antibody at a concentration of approximately 0.5 mg / mL. The control-line zone may be positioned downstream of both the methadone test line and the EDDP test line. The GAM antibody may capture gold-labeled anti-methadone antibody that is bound to methadone present in the sample and gold-labeled anti-EDDP antibody that is bound to EDDP present in the sample.
[0211] In some aspects, the multiplex lateral flow device may include an independent control line. The independent control line may be configured such that the control-line result is not affected by the test-line results. In some cases, the independent control line may comprise a chicken IgY control line. The chicken IgY control line may be used with a corresponding gold-labeled chicken IgY conjugate that flows through the lateral flow device independently of the gold-labeled anti-methadone antibody and gold-labeled anti-EDDP antibody.- 43 - 132621-0010W001 / 10715598.10Attorney Docket No. 132621 -0010WO01
[0212] In some aspects, the multiplex lateral flow device may be configured for use with a pre-mix running buffer system. A blood or plasma sample may be contacted with a pre-mix running buffer to form a pre-mixed sample prior to loading onto the multiplex lateral flow device. In some cases, the pre-mix running buffer may comprise RBI. Standards for multiplex testing may be prepared by spiking both EDDP and methadone into a plasma sample before premixing with the running buffer.
[0213] In some aspects, the multiplex lateral flow device may be configured for use with a sample volume of approximately 5 pL of plasma or serum mixed with approximately 95 pL of pre-mix running buffer. The total assay volume may be approximately 100 pL. In some cases, the sample volume may be selected to provide suitable sensitivity for quantification of both methadone and EDDP over the respective assay ranges.
[0214] In some aspects, the multiplex lateral flow device may be configured for an assay run time of approximately 30 minutes. The 30 minute run time may allow sufficient time for the sample to flow through the lateral flow device and for both the gold-labeled anti-methadone antibody conjugate and the gold-labeled anti-EDDP antibody conjugate to bind at the respective detection zones.
[0215] In some aspects, the lateral flow devices described herein may be operated according to a device operation workflow that includes a pre-insertion procedure, a sample collection and mixing procedure, and an assay processing sequence. The device operation workflow may be configured for point-of-care settings where rapid quantification of methadone and EDDP concentrations is desired.
[0216] In some aspects, the device operation workflow may include a pre-insertion procedure in which a lateral flow test-strip device is inserted into a reader prior to sample application. The lateral flow test-strip device may comprise pre-deposited assay reagents including labeled antibody conjugates on the conjugate pad and immobilized analyte:BSA conjugates on the nitrocellulose membrane. The lateral flow test-strip device may be inserted into a reader, such as an Axxin reader or an iPeak reader, before the sample is applied to the lateral flow test-strip device. The pre-insertion of the lateral flow test-strip device into the reader may allow the reader to begin monitoring the lateral flow test-strip device when the sample is applied.- 44 - 132621-0010W001 / 10715598.10Attorney Docket No. 132621 -0010WO01
[0217] In some aspects, the device operation workflow may include a sample collection procedure. A lancet may be used to draw out a drop of capillary blood from the fingertip of a subject. The capillary blood sample may be collected directly from the fingertip following the lancet puncture. In some cases, the sample collection procedure may be performed using whole blood samples obtained via fingerstick. In some cases, the sample collection procedure may be performed using plasma samples or serum samples.
[0218] In some aspects, the device operation workflow may include a sample mixing procedure. The blood or plasma sample may be mixed with a fixed volume of pre-mix running buffer to form a pre-mixed sample. In some cases, a plasma sample volume of approximately 5 pL may be mixed with approximately 95 pL of pre-mix running buffer for methadone quantification. In some cases, a plasma sample volume of approximately 10 pL may be mixed with approximately 90 pL of pre-mix running buffer for EDDP quantification. The total assay volume may be maintained at approximately 100 pL. The pre-mix running buffer system may improve flow characteristics, reduce hotspots and streaking on the nitrocellulose membrane, and improve consistency between repetitions compared to a chase buffer system.
[0219] In some aspects, the device operation workflow may include a sample loading procedure. The pre-mixed sample mixture may be transferred to the lateral flow test-strip device that has been inserted into the reader. The pre-mixed sample may be applied to the sample pad of the lateral flow test-strip device. The sample may be brought into contact with the assay either directly or through capillary action. The sample pad may receive the pre-mixed sample and allow the sample to flow through to the conjugate pad.
[0220] In some aspects, the device operation workflow may include an assay processing sequence. The pre-mixed sample may flow from the sample pad through the conjugate pad, where the sample may contact the labeled antibody conjugates. The labeled antibody conjugates may be released from the conjugate pad and flow with the sample along the flow path on the nitrocellulose membrane. Labeled antibody that is unbound to the target analyte may flow to the detection zone, where the unbound labeled antibody may be captured by the immobilized analyte:BSA conjugate and emit a detectable signal. Labeled antibody that is specifically bound to the target analyte present in the sample may flow past the detection zone without being captured.
[0221] In some aspects, the assay processing sequence may include flow of the sample through a control-line zone. The control-line zone may be positioned downstream of the - 45 - 132621-0010W001 / 10715598.10Attorney Docket No. 132621 -0010WO01detection zone or detection zones on the nitrocellulose membrane. Labeled antibody that is bound to the target analyte present in the sample may be captured at the control-line zone and emit a detectable control signal. The control signal may indicate that the sample has flowed properly through the lateral flow test-strip device.
[0222] In some aspects, the assay processing sequence may include a run time period during which the sample flows through the lateral flow test-strip device and signal develops at the detection zones. The run time may be approximately 30 minutes. In some cases, the run time may be 25 minutes or less, 20 minutes or less, or 15 minutes or less. The run time may allow sufficient time for the sample to flow through the lateral flow test-strip device and for the labeled antibody conjugates to bind at the detection zones.
[0223] In some aspects, the device operation workflow may include a signal detection and quantification procedure. Following the run time period, the reader may detect signal intensity from the test lines and control lines on the nitrocellulose membrane. The reader may be configured with test line and control line discrimination capability to distinguish between the test band and the control band. The reader may collect data from each band's intensity, with the intensity correlating with the quantity or number of immobilized conjugate molecules in each band.
[0224] In some aspects, the reader may process information regarding the intensity of the control band to determine whether the assay performed properly. The reader may process information regarding the intensity of the test band to determine a quantity of the target analytes methadone and EDDP present in the tested sample. The reader may convert the measured detected signal intensity to an analyte concentration based on a dose response curve.
[0225] In some aspects, the device operation workflow may include a results display procedure. The reader may be programmed to display one or more results based on the data collected from the detection zones. The reader may display whether the assay performed properly. The reader may display whether or not methadone and EDDP was present in the sample if the assay performed properly. The reader may display the quantity and concentration of methadone and EDDP in the sample based on a dose response curve if the target analytes were present. The results may be displayed on a connected user interface. In some cases, one or more of the displayed results may be associated with a clinical condition.- 46 - 132621-0010W001 / 10715598.10Attorney Docket No. 132621 -0010WO01
[0226] In some aspects, the device operation workflow for multiplex lateral flow devices may include quantification of both methadone and EDDP from a single sample. The reader may display whether the assay performed properly, whether or not methadone was present in the sample, the quantity of methadone in the sample if methadone was present, whether or not EDDP was present in the sample, the quantity of EDDP in the sample if EDDP was present, and the concentration ratio of methadone to EDDP in the sample based on dose response curves. The concentration ratio results may be used to calculate the methadone to metabolite ratio (MMR) of methadone to EDDP.
[0227] In some aspects, the lateral flow devices described herein may be configured to calculate a methadone to metabolite ratio (MMR) from the quantified methadone and EDDP concentrations. The MMR may be calculated as the ratio of the concentration of methadone to the concentration of EDDP in a blood or plasma sample. In some cases, the MMR may be expressed mathematically as:
[0228] where c(Methadone) represents the concentration of methadone in the sample and c(EDDP) represents the concentration of EDDP in the sample. The MMR may represent the net metabolism of methadone in a patient and may be used to assign a specific metabolic category to the patient.
[0229] In some aspects, the MMR may be interpreted using a simplified pharmacokinetic model for methadone metabolism. In the pharmacokinetic model, methadone may undergo metabolization to form a metabolite, such as EDDP, at a rate governed by a metabolization rate constant km. The metabolite may subsequently undergo renal elimination at a rate governed by an elimination rate constant ke. Under steady state conditions, where the rate of change of metabolite concentration with respect to time approaches zero, the MMR may be approximated as:
[0230] In some cases, the steady state approximation may be valid when the elimination rate constant ke is much greater than the metabolization rate constant km.
[0231] In some aspects, the calculated MMR values may be used to assign patients to metabolic categories. The metabolic categories may include an ultra-rapid metabolizer (URM) category, an extensive metabolizer (EM) category, an intermediate metabolizer (IM) category, and an ultra-slow metabolizer (USM) category. The assignment of a patient to a specific- 47 - 132621-0010W001 / 10715598.10Attorney Docket No. 132621 -0010WO01metabolic category based on the MMR may assist clinicians in making dosing decisions for patients undergoing methadone maintenance treatment.
[0232] In some aspects, underdosing may occur in patients assigned to the URM category. Patients in the URM category may metabolize methadone rapidly, which may lead to inadequate therapeutic concentrations and breakthrough withdrawal symptoms. In some cases, clinicians may consider higher methadone doses for patients assigned to the URM category based on the MMR results.
[0233] In some aspects, excessive dosing may occur in patients assigned to the IM and USM categories. Patients in the IM and USM categories may metabolize methadone slowly, which may result in drug accumulation and associated adverse effects. In some cases, clinicians may consider lower methadone doses or slower dose escalation for patients assigned to the IM and USM categories based on the MMR results.
[0234] In some aspects, the MMR may vary during the initial time period after methadone treatment has been started. The MMR values may exhibit a decline during the first few days after initiation of treatment. In some cases, the MMR values may level off and approach a steady state limit value after approximately 10 days. The time-dependent change in MMR may be measured by the lateral flow devices when a patient visits the clinic.
[0235] Referring to FIG. 1, a pharmacokinetic model for methadone metabolism and derivation of the MMR is illustrated. The pharmacokinetic model may provide the basis for interpretation of MMR values. The MMR may be calculated as a function of time based on the pharmacokinetic model.
[0236] With continued reference to FIG. 1, the MMR may be simulated as a function of time using the pharmacokinetic model. In some cases, the simulated MMR may use a metabolization rate constant km of approximately 0.001 hr1, which may be consistent with literature reported half-life values of methadone. In some cases, the simulated MMR may use an elimination rate constant ke of approximately 0.01 hr1, which may be selected to reproduce a typical experimental MMR value of approximately 10.
[0237] Referring to FIG. 2, a graph of the simulated MMR as a function of time is depicted. The graph may show that the MMR varies during the initial time period after methadone treatment has been started. In some cases, the MMR may take up to 10 days before the MMR- 48 - 132621-0010W001 / 10715598.10Attorney Docket No. 132621 -0010WO01values level off and approach a limit value. Following the MMR value as the MMR approaches a steady state number may provide initial dosing feedback and assistance for clinicians.
[0238] In some aspects, the data analyzer may be configured to record MMR values for each patient over time. The data analyzer may perform linear regression calculations on the recorded MMR data. The data analyzer may deliver a day-by-day evaluation of the patient's assigned metabolic category based on the recorded data and calculations. In some cases, the MMR test may be applied at least every other day during the first 10 days of induction, followed by once a month for the next three months and then quarterly after that.
[0239] In some aspects, the MMR results may be combined with other clinical information to determine personalized dose adjustments. The other clinical information may include information on continued use of illicit substances, current medications, cravings, withdrawal status, and level of opioid tolerance. The combination of pharmacokinetic data from the lateral flow device with other clinical information may support personalized dose adjustments for patients in the induction or maintenance stages of medication assisted treatment.
[0240] In some aspects, the lateral flow devices and associated test systems described herein may be configured for longitudinal monitoring of methadone to metabolite ratio (MMR) values over time. The longitudinal monitoring may allow for identification of long-term changes in methadone metabolization in a patient. In some cases, collected measurements and data may be collated and analyzed over time to track changes in a patient's metabolic profile.
[0241] In some aspects, the data analyzer may be configured to perform longitudinal MMR tracking. The data analyzer may record MMR values for each patient at each clinic visit. The recorded MMR values may be stored in a patient database along with associated timestamps. In some cases, the data analyzer may track changes in MMR values over the course of treatment to identify trends in methadone metabolization.
[0242] In some aspects, the data analyzer may be configured to perform linear regression analysis on the recorded MMR data. The linear regression analysis may be used to model the time-dependent change in MMR values. In some cases, the linear regression analysis may be used to predict when the MMR values will approach a steady state limit value. The data analyzer may deliver a day-by-day evaluation of the patient's assigned metabolic category based on the recorded data and linear regression calculations.- 49 - 132621-0010W001 / 10715598.10Attorney Docket No. 132621 -0010WO01
[0243] In some aspects, the MMR values may exhibit a characteristic time-dependent profile during the initial period after methadone treatment has been started. The MMR values may show a decline during the first few days after initiation of treatment. In some cases, the MMR values may level off and approach a steady state limit value after approximately 10 days. Following the MMR value as the MMR approaches a steady state number may provide initial dosing feedback and assistance for clinicians.
[0244] Referring to FIG. 2, the simulated MMR as a function of time may illustrate the timedependent change in MMR values. The graph may show that the MMR varies during the initial time period after methadone treatment has been started. In some cases, the MMR may take up to 10 days before the MMR values level off and approach a limit value.
[0245] In some aspects, the test systems described herein may be configured for use according to a testing schedule that varies based on the stage of treatment. The testing schedule may include an induction phase testing schedule, a maintenance phase testing schedule, and a long-term monitoring testing schedule.
[0246] In some aspects, the induction phase testing schedule may include MMR testing at least every other day during the first 10 days of treatment. The frequent testing during the induction phase may allow clinicians to monitor the time-dependent change in MMR values as the MMR approaches a steady state value. In some cases, the induction phase testing may provide daily MMR values that are indicative of the patient's metabolic response to methadone.
[0247] In some aspects, the maintenance phase testing schedule may include MMR testing once a month for the first three months following the induction phase. The monthly testing during the maintenance phase may allow clinicians to monitor the stability of the patient's metabolic profile after the MMR has reached a steady state value. In some cases, the maintenance phase testing may identify changes in metabolization that occur after the initial stabilization period.
[0248] In some aspects, the long-term monitoring testing schedule may include MMR testing on a quarterly basis following the maintenance phase. The quarterly testing may allow clinicians to monitor for long-term changes in methadone metabolization. In some cases, the quarterly testing may identify changes in metabolization that result from changes in patient health status, concurrent medications, or other factors that may affect methadone metabolism.- 50 - 132621-0010W001 / 10715598.10Attorney Docket No. 132621 -0010WO01
[0249] In some aspects, the data analyzer may be configured to create a personalized metabolic profile for each patient. The personalized metabolic profile may include recorded MMR values over time, assigned metabolic categories, and linear regression analysis results. In some cases, the personalized metabolic profile may include the patient's steady state MMR value and the time required to reach steady state.
[0250] In some aspects, the personalized metabolic profile may be used to assign a patient to a metabolic category. The metabolic categories may include an ultra-rapid metabolizer (URM) category, an extensive metabolizer (EM) category, an intermediate metabolizer (IM) category, and an ultra-slow metabolizer (USM) category. The assignment of a patient to a specific metabolic category based on the personalized metabolic profile may assist clinicians in making dosing decisions.
[0251] In some aspects, the personalized metabolic profile may be combined with other clinical information to determine personalized dose adjustments. The other clinical information may include information on continued use of illicit substances, current medications, cravings, withdrawal status, and level of opioid tolerance. In some cases, the combination of the personalized metabolic profile with other clinical information may support personalized dose adjustments for patients in the induction or maintenance stages of medication assisted treatment.
[0252] In some aspects, the data analyzer may be configured to generate alerts or notifications based on changes in the personalized metabolic profile. In some cases, the data analyzer may generate an alert when the MMR value changes by more than a threshold amount between consecutive measurements. In some cases, the data analyzer may generate a notification when the patient's assigned metabolic category changes based on the longitudinal MMR data.
[0253] In some aspects, the personalized metabolic profile may be updated at each clinic visit when an MMR measurement is performed. The data analyzer may recalculate the linear regression analysis and update the assigned metabolic category based on the new MMR data. In some cases, the personalized metabolic profile may provide a historical record of the patient's metabolic response to methadone treatment over time.
[0254] Referring to FIG. 3, the test systems described herein may integrate a lateral flow test-strip device, a pre-mix running buffer, sample handling components, and a reader to provide quantitative methadone and EDDP concentrations for clinical decision-making. The integration- 51 - 132621-0010W001 / 10715598.10Attorney Docket No. 132621 -0010WO01of the test system components may enable point-of-care quantification of methadone and EDDP in blood or plasma samples.
[0255] In some aspects, the lateral flow test-strip device may comprise a sample pad, a conjugate pad, a nitrocellulose membrane, and an absorbent pad arranged sequentially along a flow path. The sample pad may be configured to receive a pre-mixed sample comprising a blood or plasma sample that has been contacted with a pre-mix running buffer. The conjugate pad may comprise pre-deposited labeled antibody conjugates, including gold-labeled anti-methadone antibody conjugate and gold-labeled anti-EDDP antibody conjugate in multiplex configurations. The nitrocellulose membrane may comprise one or more detection zones and a control-line zone. The absorbent pad may be configured to wick fluid through the lateral flow test-strip device and collect excess sample.
[0256] With continued reference to FIG. 3, the lateral flow test strip device 100 comprises a sample pad 102 positioned at the sample application end of the device. The sample pad 102 is configured to receive a pre-mixed sample comprising whole blood, plasma, or serum that has been contacted with a pre-mix running buffer. In one embodiment, the sample pad 102 comprises an FR1 blood separation pad having a length of approximately 15 mm.
[0257] A conjugate pad 104 is positioned downstream of the sample pad 102 along the flow path. The conjugate pad 104 comprises a labeled anti-methadone antibody or a labeled anti-EDDP antibody immobilized thereon. In one embodiment, the conjugate pad 104 comprises an Ahlstrom 8980 conjugate pad having a length of approximately 10 mm, pretreated with a pretreatment buffer. In one embodiment, the labeled anti-methadone antibody comprises a mouse anti-methadone monoclonal antibody conjugated to gold nanoparticles at OD7.5, dispensed at approximately 10 pL / cm. In another embodiment, the labeled anti-EDDP antibody comprises a mouse anti-EDDP monoclonal antibody conjugated to gold nanoparticles at OD7.5, dispensed at approximately 12 pL / cm.
[0258] A nitrocellulose membrane 110 is positioned downstream of the conjugate pad 104 along the flow path. In one embodiment, the nitrocellulose membrane 110 comprises a CN140 membrane having a width of approximately 25 mm. The nitrocellulose membrane 110 comprises a first detection zone 112, and in some embodiments a second detection zone, and a control-line zone 116 positioned sequentially along the flow path.- 52 - 132621-0010W001 / 10715598.10Attorney Docket No. 132621 -0010WO01
[0259] The first detection zone 112 comprises an immobilized methadone-BSA conjugate configured to capture labeled anti-methadone antibody that is unbound to methadone in the sample. In one embodiment, the methadone-BSA conjugate is striped onto the nitrocellulose membrane 110 at a concentration of approximately 0.5 mg / mL at 1 pL / cm.
[0260] In other embodiments, the second detection zone comprises an immobilized EDDP-BSA conjugate configured to capture labeled anti-EDDP antibody that is unbound to EDDP in the sample. The second detection zone can be either upstream of downstream of the first detection zone in the lateral flow, and is upstream of the control line zone 116. In one embodiment, the EDDP -B SA conjugate is striped onto the nitrocellulose membrane 110 at a concentration of approximately 0.125 mg / mL at 1 pL / cm.
[0261] The control-line zone 116 is positioned downstream of the first detection zone 112 and in some embodiments the second detection zone. In this exemplified embodiment, the control-line zone 116 comprises a goat anti -mouse antibody configured to capture labeled antibody that has flowed through the first detection zone 112 (and the second detection zone when present), thereby confirming proper sample flow and assay function. In one embodiment, the goat anti-mouse antibody is striped at a concentration of approximately 0.5 mg / mL at 1 pL / cm.
[0262] An absorbent pad 118 is positioned at the downstream end of the lateral flow test strip device 100. The absorbent pad 118 is configured to wick fluid through the device and collect excess sample. In one embodiment, the absorbent pad 118 comprises an Ahlstrom grade 222 absorbent pad having a length of approximately 20 mm.
[0263] The components of the lateral flow test strip device 100 are mounted on a backing card. In one embodiment, the backing card has a length of approximately 60 mm.
[0264] In operation, when a pre-mixed sample is applied to the sample pad 102, the sample flows along the flow path and reconstitutes the labeled anti-methadone antibody and / or the labeled anti-EDDP antibody from the conjugate pad 104. Methadone present in the sample binds to the labeled anti-methadone antibody, and EDDP present in the sample binds to the labeled anti-EDDP antibody. Labeled antibody that remains unbound flows to the respective detection zones 112 and is captured by the immobilized BSA conjugates, producing a detectable signal. Labeled antibody that is bound to analyte flows past the detection zones and is captured at the control-line zone 116. The signal intensity at each detection zone is inversely proportional to the- 53 - 132621-0010W001 / 10715598.10Attorney Docket No. 132621 -0010WO01concentration of the respective analyte in the sample, consistent with an inhibition lateral flow assay format.
[0265] With continued reference to FIG. 3, the pre-mix running buffer may be configured to facilitate sample preparation prior to loading onto the lateral flow test-strip device. A blood or plasma sample may be contacted with the pre-mix running buffer to form a pre-mixed sample. In some cases, a plasma sample volume of approximately 5 pL may be mixed with approximately 95 pL of pre-mix running buffer for methadone quantification. In some cases, a plasma sample volume of approximately 10 pL may be mixed with approximately 90 pL of premix running buffer for EDDP quantification. The pre-mix running buffer system may improve flow characteristics, reduce hotspots and streaking on the nitrocellulose membrane, and improve consistency between repetitions compared to a chase buffer system.
[0266] In some aspects, the sample handling components may include a lancet for obtaining a capillary blood sample from a fingertip of a subject. The capillary blood sample may be collected directly from the fingertip following the lancet puncture. The capillary blood sample may be mixed with a fixed volume of pre-mix running buffer to form a pre-mixed sample. The pre-mixed sample mixture may be transferred to the lateral flow test-strip device, where the sample may be brought into contact with the assay either directly or through capillary action.
[0267] In some aspects, the lateral flow test-strip device may be inserted into a reader prior to sample application. The reader may comprise a light source and a detector configured to measure signal intensity from the detection zones on the lateral flow test-strip device. The reader may be configured to begin monitoring the lateral flow test-strip device when the sample is applied. In some cases, the reader may comprise an Axxin reader. In some cases, the reader may comprise an iPeak reader.
[0268] In some aspects, the pre-mixed sample may flow from the sample pad through the conjugate pad when the pre-mixed sample is loaded onto the lateral flow test-strip device. The pre-mixed sample may contact the labeled antibody conjugates on the conjugate pad. The labeled antibody conjugates may be released from the conjugate pad and flow with the pre-mixed sample along the flow path on the nitrocellulose membrane. The pre-treatment buffer on the conjugate pad may facilitate release of the labeled antibody conjugates when the pre-mixed sample is applied to the lateral flow test-strip device.- 54 - 132621-0010W001 / 10715598.10Attorney Docket No. 132621 -0010WO01
[0269] In some aspects, the lateral flow test-strip devices described herein may operate according to an inhibition lateral flow format. In the inhibition lateral flow format, labeled antibody that is unbound to the target analyte may flow to the detection zone, where the unbound labeled antibody may be captured by the immobilized analyte:BSA conjugate and emit a detectable signal. Labeled antibody that is specifically bound to the target analyte present in the pre-mixed sample may flow past the detection zone without being captured. Accordingly, the signal intensity at the detection zone may be inversely related to the concentration of the target analyte in the pre-mixed sample.
[0270] In some aspects, the gold-labeled anti-methadone antibody that is unbound to methadone may flow in the flow path to a first detection zone comprising an immobilized methadone:BSA conjugate. The unbound gold-labeled anti-methadone antibody may be captured at the first detection zone and emit a detectable signal. The gold-labeled anti-methadone antibody that is specifically bound to methadone present in the pre-mixed sample may flow past the first detection zone without being captured.
[0271] In some aspects, the gold-labeled anti-EDDP antibody that is unbound to EDDP may flow in the flow path to a second detection zone comprising an immobilized EDDP:BSA conjugate. The unbound gold-labeled anti-EDDP antibody may be captured at the second detection zone and emit a detectable signal. The gold-labeled anti-EDDP antibody that is specifically bound to EDDP present in the pre-mixed sample may flow past the second detection zone without being captured.
[0272] In some aspects, the labeled antibody that is bound to the target analyte present in the pre-mixed sample may flow to a control-line zone positioned downstream of the detection zones. The control-line zone may comprise a goat anti-mouse (GAM) antibody configured to capture the labeled antibody that is bound to the target analyte. The captured labeled antibody may emit a detectable control signal at the control-line zone. The control signal may indicate that the premixed sample has flowed properly through the lateral flow test-strip device.
[0273] In some aspects, the reader may be configured with test line and control line discrimination capability. The test line and control line discrimination capability may allow the reader to distinguish between the test band and the control band on the lateral flow test-strip device. The reader may collect data from each band's intensity, with the intensity correlating with the quantity or number of immobilized conjugate molecules in each band. The reader may process the data collected from reading each of the bands separately.- 55 - 132621-0010W001 / 10715598.10Attorney Docket No. 132621 -0010WO01
[0274] In some aspects, the reader may process information regarding the intensity of the control band to determine whether the assay performed properly. The control band intensity may indicate that the pre-mixed sample has flowed properly through the lateral flow test-strip device and that the assay reagents are functioning as expected. The reader may process information regarding the intensity of the test band to determine a quantity of the target analytes methadone and EDDP present in the tested sample.
[0275] In some aspects, a data analyzer may be configured to convert the detected signal intensity to analyte concentration based on a dose response curve. The data analyzer may analyze reader data using a four-parameter logistic (4PL) curve fit. The 4PL curve fit may be used to generate a dose response curve from standard concentrations of known analyte levels. Values may be interpolated from the 4PL curve to determine analyte concentration from the measured signal intensity.
[0276] In some aspects, the reader may be programmed to display one or more results based on the data collected from the detection zones. The reader may display whether the assay performed properly. The reader may display whether or not methadone was present in the premixed sample if the assay performed properly. The reader may display the quantity and concentration of methadone in the pre-mixed sample based on a dose response curve if methadone was present. The reader may display whether or not EDDP was present in the premixed sample if the assay performed properly. The reader may display the quantity and concentration of EDDP in the pre-mixed sample based on a dose response curve if EDDP was present. The results may be displayed on a connected user interface.
[0277] In some aspects, the reader may be configured for use with multiplex lateral flow test-strip devices that detect the concentration of both methadone and EDDP. The reader may display the concentration ratio of methadone to EDDP in the pre-mixed sample based on dose response curves. The concentration ratio results may be used to calculate the methadone to metabolite ratio (MMR) of methadone to EDDP. The MMR may represent the net metabolism and may be used to assign a specific metabolic category to a patient.
[0278] In some aspects, the assay run time may refer to the time period between loading the pre-mixed sample onto the lateral flow test-strip device and detecting the signal intensity from the detection zones. The assay run time may be approximately 30 minutes. In some cases, the assay run time may be 25 minutes or less, 20 minutes or less, or 15 minutes or less. The assay- 56 - 132621-0010W001 / 10715598.10Attorney Docket No. 132621 -0010WO01run time may allow sufficient time for the pre-mixed sample to flow through the lateral flow test-strip device and for the labeled antibody conjugates to bind at the detection zones.
[0279] In some aspects, the lateral flow test-strip device may process the pre-mixed sample, and the reader may determine the methadone and EDDP concentrations. The results may be available within the assay run time. One or more of the displayed results may be associated with a clinical condition. The displayed results may provide point-of-care objective feedback on a patient's methadone dosing based on pharmacokinetic information.
[0280] A number of implementations have been described. Nevertheless, it will be understood that various modifications may be made without departing from the spirit and scope of the disclosure. Accordingly, other implementations are within the scope of the following claims.EXAMPLES
[0281] The examples herein are intended to illustrate certain aspects of the present disclosure to one of ordinary skill in the art. However, the examples are not intended to limit the scope of the present disclosure.Example 1: Lateral Flow Test-Strip Device Architecture
[0282] A lateral flow test-strip device was constructed for quantifying methadone and EDDP in blood or plasma samples. The device architecture comprised the following components arranged sequentially along a flow path: an FR1 sample pad with a length of 15 mm configured to receive a pre-mixed sample comprising whole blood, plasma, or serum that had been premixed with buffer; an Ahlstrom 8980 conjugate pad with a length of 10 mm pretreated with PPI pretreatment buffer; a CN140 nitrocellulose membrane with a width of 25 mm; and a grade 222 absorbent pad with a length of 20 mm. The components were mounted on a 60 mm backing card.
[0283] The conjugate pad contained gold-labeled antibody conjugates. The methadone gold conjugate comprised ABMTD-0402 anti-methadone antibody conjugated to 40 nm gold nanoparticles at OD7.5, dispensed at a spray rate of 10 pL / cm. The EDDP gold conjugate comprised DMAB3910 anti-EDDP antibody conjugated to 40 nm gold nanoparticles at OD7.5, dispensed at a spray rate of 12 pL / cm.
[0284] The nitrocellulose membrane comprised test lines and a control line striped at 1 pL / cm. The methadone test line comprised AGMTD-0302 methadone:BSA conjugate at a - 57 - 132621-0010W001 / 10715598.10Attorney Docket No. 132621 -0010WO01concentration of 0.5 mg / mL. The EDDP test line comprised DAG-NS001 EDDP:BSA conjugate at a concentration of 0.125 mg / mL. The control line comprised goat anti-mouse (GAM) antibody at a concentration of 0.5 mg / mL.Example 2: Gold Conjugate Development
[0285] Passive conjugation of methadone antibodies (DMAB7650, HM384, ABMTD-0402) and EDDP antibodies (DMAB3910, HM381) to 40 nm gold nanoparticles was investigated using various conjugation buffers. The following buffers were tested: 10 mM HEPES buffer at pH 7-8; 10 mM MES buffer at pH 5.80; 100 mM MES buffer at pH 5.80; 10 mM TAPS buffer at pH 8.50; 20 mM Borate buffer at pH 8.00; 200 mM Carbonate buffer at pH 9.00; PBS at pH 7.20-7.60; and 10 mM KPOM at pH 7.00.
[0286] A gold stability test was performed to determine the minimum concentration of antibody required to stabilize the gold conjugate solution. The gold stability test involved adding 10% sodium chloride to the gold conjugate solution. The minimum concentration of antibody required to stabilize the gold solution was indicated by the condition in which the color of the gold conjugate solution did not change from red to blue upon addition of the sodium chloride. A color change from red to blue indicated that the gold conjugate had aggregated due to sub-optimal levels of antibody coating the particles.
[0287] The antibodies were diluted in each buffer to concentrations of 0, 6, 8, 10, 12, and 14 pg / mL, and OD6 40 nm gold colloid was added to each dilution. The antibody concentration that prevented color change upon sodium chloride addition was selected as the minimum antibody concentration for stable conjugate formation.Example 3: Reagent Pair Testing
[0288] Conjugates were prepared using the optimal conditions defined in Example 2 and used in half-dipstick testing against different methadone test line reagents (DAG410, AGMTD-0302) and EDDP test line reagents (DAG-NS001). Half-dipstick testing was performed using CN140 and CN180Dx nitrocellulose membranes with a control line comprising GAM at 0.5 mg / mL, methadone test lines at 0.5 mg / mL, and EDDP test lines at 0.5 mg / mL, all striped at 1 pL / cm. The conjugates tested included MTD ABMTD-0402 at OD2 and EDDP DMAB3910 at OD2. The absorbent pad was Ahlstrom grade 222 at 20 mm, and the running buffer was PBS with 1% Tween-20.- 58 - 132621-0010W001 / 10715598.10Attorney Docket No. 132621 -0010WO01
[0289] Results indicated that the CN140 membrane provided better aesthetics and OD5 gold gave strong test lines. These conditions were used as a benchmark for further testing. The different conjugates were tested against all the different test lines to find the optimal reagent pairings for methadone and for EDDP. Results showed promising signs of inhibition. The supplier pairs performed better than pairs formed between one supplier's gold conjugate antibody with a different supplier's test line. The best performing pairs were the Fortis reagent pair (ABMTD-0402 conjugate with AGMTD-0302 test line) for methadone and the Creative Diagnostics reagent pair (DMAB3910 conjugate with DAG-NS001 test line) for EDDP.Example 4: Conjugate Pad Pre-treatment Investigation
[0290] Two different conjugate pads and a range of different conjugate pad pre-treatment buffers were tested to establish the best conditions for both methadone and EDDP. The conjugate pads tested were Ahlstrom 8980 (chopped glass fibers with binder, wicking rate 2.2 s / 4cm) and Ahlstrom 6614 (polyester fibers with binder, wicking rate 2.5 s / 4cm). The pretreatment buffers tested were: PPI comprising Tergitol at 2% w / v, HEPES at 1.192% w / v, sodium tetraborate decahydrate at 0.192% w / v, and BSA at 0.1% w / v; PP2 comprising Trizma base at 1.21% w / v, BSA at 0.5% w / v, and Tween 20 at 0.25% w / v; and PP4 comprising BSA at 2.5%, NaCl at 0.8%, Tergitol at 0.42%, Na2HPO4at 0.14%, KC1 at 0.02%, and KJLPC^ at 0.02%.
[0291] Methadone testing showed different release profiles with the different pads and pretreatments and some displacement over the short range tested; however, line quality was sub-optimal. EDDP testing showed variation in visual signal intensity with the negative standard between the different pads and pre-treatments, with all showing good displacement and better line quality than observed for methadone.
[0292] Methadone testing was repeated with a lower gold conjugate content with the OD reduced from OD10 to OD5. Reducing the amount of gold in the system improved the aesthetics with better line quality and no background staining visible. The reduced gold OD also improved the displacement. This data set showed a clear distinction between performance with the two different conjugate pads, with the 8980 pad showing better inhibition than the 6614 pad. For methadone, the 8980 pad with PPI pretreatment buffer was selected for further investigation. For EDDP, the 6614 pad with PP4 pretreatment buffer was initially selected for further investigation.- 59 - 132621-0010W001 / 10715598.10Attomey Docket No. 132621 -0010WO01Example 5: Running Buffer Investigation
[0293] Six different running buffer formulations were tested for both methadone and EDDP.The running buffer formulations tested were: RBI comprising 50 mM Na2COs, 60 mM NaCl, 10 mM EDTA, 0.5% Tween-20 (wt:vol), 0.05% Proclin 300 (vol / vol), at pH 9.25; RB2 comprising 100 mMNa2COs, 60 mMNaCl, 10 mMEDTA, 0.5% Tween20, 0.05% ProCiin 300, at pH 10.6; RB3 comprising phosphate buffered saline, 0.05% Tween20, 0.05% NaNs, at pH 7.35-7.40; RB4 comprising Tris buffered saline, 0.1% Triton X100, 0.01% NaNs, at pH 8.18-8.22; RB5 comprising 0.5% Na2HPO4 I2H2O, 0.6% NaCl, 1.6% Sodium Caseinate, 0.5% EDTA, 0.095% NaNs, at pH 7.0-8.0; and RB6 comprising 0.7% Na2HPO4, 0.5% Casein, 0.9% NaCl, 0.09% NaNs, 0.25% Kanamycin Sulfate, 1% Detergent, at pH 7.0-8.0.
[0294] The selected EDDP pre-treated pads were tested with the test line concentration at 0.25 mg / mL and both OD5 and OD7.5 gold with an increased number of standards to cover the required assay range. Results showed that PP4 caused a change in curve shape, providing good displacement between each sample concentration tested over the full assay range. The preferred running buffer for EDDP was RB 1.
[0295] The selected methadone pre-treated pads were tested using OD7.5 gold (for consistency with the EDDP conjugate OD), test line concentration at 0.25 mg / mL, and a full range of standards to cover the required assay range. Results showed that the combination of PPI with RBI gave better displacement and displayed a more consistent test response compared to PP2 with RB3, which was more sensitive so gave greater displacement at lower concentrations before plateauing towards the mid to high standards. The preferred running buffer for methadone was RBI.Example 6: Chase vs Pre-mix Sample Handling
[0296] Testing was performed to investigate the effect of pre-mixing a plasma sample with a pre-mix running buffer before loading the pre-mix onto the test-strip device, in comparison to sample followed by chase buffer. Sample volume was 15 pL and buffer volume was 85 pL for both systems. The buffer used was RBI for EDDP and RBI and RB3 for methadone.
[0297] For both EDDP and methadone, the pre-mix running buffer system improved flow characteristics, reduced hotspots and streaking, and also improved consistency between repetitions. RBI showed better performance for methadone than RB3. Based on these results, the pre-mix running buffer system with RB 1 was selected for both methadone and EDDP assays.- 60 - 132621-0010W001 / 10715598.10Attorney Docket No. 132621 -0010WO01Example 7: Methadone Assay Performance in Plasma Matrix
[0298] The performance of the methadone lateral flow assay was assessed using plasma matrix. A full range of standards in 5 pL plasma was assessed with visual scoring and iPeak reader. N=5 replicates were tested. Data was analyzed using 4PL curve fit with values interpolated from the curve to assess accuracy and precision.The results are shown in Table 1.Table 1: Methadone assay performance in plasma matrix.Concentration (ng / mL) Mean %CV % Recovery1800 1699.65 7.8 94.41600 1497.48 9.1 93.61200 1143.63 16.6 95.3800 729.83 16.1 91.2500 452.61 11.5 90.5200 184.03 12.4 92.075 72.71 12.8 96.950 47.30 37.7 94.6
[0299] The curve showed good recovery across the range with values ranging from 90.5% to 96.9% for concentrations at or above 75 ng / mL. Precision was good for concentrations above 50 ng / mL, with %CV values ranging from 7.8% to 16.6%. The 50 ng / mL concentration showed higher variability at 37.7% CV. The required assay range of 75-1600 ng / mL was achieved.Example 8: EDDP Assay Performance in Plasma Matrix
[0300] The performance of the EDDP lateral flow assay was assessed using plasma matrix. A full range of standards in 10 pL plasma was assessed with visual scoring and iPeak reader. N=5 replicates were tested. Data was analyzed using 4PL curve fit with values interpolated from the curve to assess accuracy and precision. The results are shown in Table 2.Table 2: EDDP assay performance in plasma matrix.- 61 - 132621-0010W001 / 10715598.10Attorney Docket No. 132621 -0010WO01Concentration (ng / mL) Mean %CV % Recovery600 533.33 9.2 88.9500 469.30 7.3 93.9250 274.79 7.2 109.9100 106.76 7.1 106.850 48.25 25.2 96.525 25.51 13.5 102.15 6.28 46.7 125.52.5 3.63 54.3 145.3
[0301] The curve showed good recovery across the range with the exception of the lowest concentrations. Recovery values ranged from 88.9% to 109.9% for concentrations at or above 25 ng / mL. Precision was reasonable across the higher concentrations, with %CV values ranging from 7.1% to 13.5% for concentrations at or above 25 ng / mL. The lowest concentrations (2.5 ng / mL and 5 ng / mL) showed higher variability. The required assay range of 5-500 ng / mL was nearly achieved.Example 9: Matrix Effect Assessment (Plasma vs Serum)
[0302] The performance of both the methadone and EDDP lateral flow assays was assessed in serum matrix to investigate any sample matrix effects. A full range of standards in 5 pL serum (for methadone) and 10 pL serum (for EDDP) was assessed with visual scoring and iPeak reader. N=5 replicates were tested. Data was analyzed using 4PL curve fit with values interpolated from the curve to assess accuracy and precision. The methadone serum results are shown in Table 3; and the EDDP serum results are shown in Table 4.Table 3: Methadone assay performance in serum matrix.Concentration (ng / mL) Mean %CV %Recovery1800 1928.10 4.2 107.11600 1577.46 8.9 98.61200 1250.53 15.5 104.2- 62 - 132621-0010W001 / 10715598.10Attorney Docket No. 132621 -0010WO01Concentration (ng / mL) Mean %CV %Recovery800 783.95 21.7 98.0500 527.34 17.1 105.5200 200.67 20.1 100.375 56.57 28.7 75.450 43.76 24.2 87.5Table 4: EDDP assay performance in serum matrix.Concentration (ng / mL) Mean %CV %Recovery600 566.52 5.8 94.4500 479.14 7.5 95.8250 262.82 9.4 105.1100 102.42 12.5 102.450 50.04 6.9 100.125 24.73 7.9 98.95 7.71 20.3 154.22.5 3.78 11.6 151.2
[0303] Both tests showed minimal matrix effect between plasma and serum with similar curve performance. The curve shape, curve position, and assay performance were similar between plasma and serum samples for both methadone and EDDP quantification.Example 10: Patient Sample Validation
[0304] Patient plasma samples with known methadone and EDDP concentrations were tested on the lateral flow devices to assess whether they could be accurately quantified from the curves. N=3 replicates were tested for each patient sample. Methadone samples were tested with 5 pL sample volume and EDDP samples were tested with 10 pL sample volume. The methadone patient sample results are shown in Table 5.Table 5: Methadone patient plasma sample results.- 63 - 132621-0010W001 / 10715598.10Attomey Docket No. 132621 -0010WO01NominalSampleCone Rep 1 Rep 2 Rep 3 Mean SD %CV % Recovery No.(ng / mL)1 294 256.36 403.64 329.29 329.76 60.13 18.2 112.2 2 107 117.22 97.26 74.01 96.16 17.66 18.4 89.9 3 34 49.31 45.73 26.79 40.61 9.88 24.3 119.4 4 32 85.83 85.20 57.56 76.20 13.18 17.3 238.1 5 396 436.69 263.73 329.29 343.24 71.30 20.8 86.7 6 396 609.07 461.09 499.61 523.26 62.68 12.0 132.1The EDDP patient sample results are shown in Table 6.Table 6: EDDP patient plasma sample results.NominalSampleCone Rep 1 Rep 2 Rep 3 Mean SD %CV % Recovery No.(ng / mL)1 35 63.40 78.00 74.37 71.92 6.20 8.6 205.5 2 14 26.04 17.51 21.45 21.67 3.48 16.1 154.8 3 18 22.50 23.82 30.64 25.66 3.57 13.9 142.5 4 5 8.82 8.82 9.06 8.90 0.11 1.3 178.0 5 16 21.45 16.35 13.95 17.25 3.13 18.1 107.8 6 40 62.22 58.44 55.56 58.74 2.73 4.6 146.8
[0305] Methadone results showed good correlation between lateral flow test results and nominal values for samples within the assay range. Sample 3 and Sample 4 were at very low concentrations below the lower limit of quantification of the curve, which contributed to the higher recovery values observed. EDDP results showed less accurate correlation between lateral flow and nominal values, which was attributed to sample concentrations being at the very low end of the curve.- 64 - 132621-0010W001 / 10715598.10Attorney Docket No. 132621 -0010WO01Example 11: Multiplex Assay Development
[0306] A multiplex lateral flow test system with both test lines for methadone and EDDP on a single strip was developed and tested. Devices were prepared using the preferred methadone assay parameters (8980 conjugate pad with PPI pretreatment buffer) with gold conjugates mixed on the conjugate pad. Test lines were sprayed with either methadone first or EDDP first to assess the effect of test line order. Standards were prepared by spiking both EDDP and methadone into a plasma sample before pre-mixing with RBI.
[0307] Results showed that the curve shapes for both methadone and EDDP were similar regardless of the order of the test lines on the membrane. However, the membranes with the EDDP test line first showed better displacement at the lower end of the curves. The EDDP assay was also evaluated using the 8980 pad (preferred for methadone) in place of the 6614 pad originally selected for EDDP. Results showed slightly different curve shapes between devices with the two different pads, but the results with the 8980 pad were still functional and showed better distinction between the lower concentrations of the standards. These results confirmed that a multiplex test system quantifying both methadone and EDDP in the same lateral flow teststrip device is feasible.
[0308] Results showed that the curve shapes for both methadone and EDDP were similar regardless of the order of the test lines on the membrane. However, the membranes with the EDDP test line first showed better displacement at the lower end of the curves. The EDDP assay was also evaluated using the 8980 pad (preferred for methadone) in place of the 6614 pad originally selected for EDDP. Results showed slightly different curve shapes between devices with the two different pads, but the results with the 8980 pad were still functional and showed better distinction between the lower concentrations of the standards. These results confirmed that a multiplex test system quantifying both methadone and EDDP in the same lateral flow teststrip device is feasible.Example 12: NIDA Phase I Clinical Study - Retrospective Patient Sample Validation
[0309] A Phase I NIDA Blueprint MedTech SBIR Grant study was conducted to validate the CAR! Metabolic Assessment System (CMAS) for quantifying methadone and EDDP in human plasma samples. Six native, retrospective methadone patient plasma samples were sourced from NMS Labs. The sample concentration ranges were at the low end of the clinical range, with methadone concentrations ranging from 32 to 396 ng / mL and EDDP concentrations- 65 - 132621-0010W001 / 10715598.10Attorney Docket No. 132621 -0010WO01ranging from 5 to 40 ng / mL. The clinical methadone range was 75 to 1,600 ng / mL and the clinical EDDP range was 5 to 500 ng / mL.
[0310] Three replicates were run for each sample. The methadone assay used a sample volume of 5 pL per replicate and the EDDP assay used a sample volume of 10 pL per replicate. All measurements were performed on an iPeak Reader. The methadone results are shown in Table 7; and the EDDP results are shown in Table 8.Table 7: Methadone CMAS results from retrospective patient plasma samples.MeanSample N SD(ng / mL)1 3 330 742 3 96 223 3 41 124 3 76 165 3 343 876 3 523 77Table 8: EDDP CMAS results from retrospective patient plasma samples.MeanSample N SD(ng / mL)1 3 72 82 3 22 43 3 26 44 3 9 0.15 3 17 46 3 59 3- 66 - 132621-0010W001 / 10715598.10Attomey Docket No. 132621 -0010WO01
[0311] The samples were classified into metabolic categories based on the methadone to metabolite ratio (MMR). The metabolic categories were defined as: ultra-rapid metabolizer (URM) with MMR <5; extensive metabolizer (EM) with MMR >5 and <12; intermediate metabolizer (IM) with MMR >12 and <16; and ultra-slow metabolizer (USM) with MMR >16. Five of six samples were classified into the same metabolic categories as the LC / MS reference method. The MMR classification results are shown in Table 9.Table 9: MMR classification comparison between LC / MS reference method and CMAS.LC / MS LC / MS CMAS CMASLC / MS LC / MS CMAS CMAS Sample MTD EDDP MTD EDDPMMR Category MMR Category (ng / mL) (ng / mL) (ng / mL) (ng / mL)1 294 35 8 EM 330 72 5 EM 2 107 14 8 EM 96 22 4 URM 3 34 18 2 URM 41 26 2 URM 4 32 5 6 EM 76 9 9 EM 5 396 16 25 USM 343 17 20 USM 6 396 40 10 EM 523 59 9 EM
[0312] The results demonstrated correlation between the CMAS lateral flow test system and the LC / MS reference method for both methadone and EDDP quantification, with 5 of 6 samples classified into the same metabolic categories.Example 13: Prospective Clinical Feasibility Study - Trough and Peak Sample Detection
[0313] A WCG-IRB approved 5-patient clinical feasibility study was administered by the CRO Solaris Research International. Patients were recruited through Acadia Healthcare, the largest provider of methadone treatment in the United States. Five patients currently enrolled in methadone maintenance therapy with a daily dose of at least 10 mg were included in the study.
[0314] For each patient, a venous blood draw (trough sample) was taken upon arrival at the study site. Each patient was then given their oral dose of methadone and asked to wait for 3 hours, after which a second venous blood draw (peak sample) was taken. Each blood sample was processed to plasma by spinning in a centrifuge for 10 minutes.- 67 - 132621-0010W001 / 10715598.10Attorney Docket No. 132621 -0010WO01
[0315] The resulting plasma samples were each tested on 3 methadone cassettes and 3 EDDP cassettes, for a total of 60 lateral flow cassettes tested across 10 sample types. Samples for the methadone cassettes were diluted with buffer at a 1:10 ratio (10 pL plasma to 90 pL buffer), while samples for the EDDP cassettes were diluted with buffer at a 1:20 ratio (5 pL plasma to 95 pL buffer). In all cases, 100 pL of diluted sample was loaded into the test cassette. Each cassette was read by the instrument 30 minutes after the sample was loaded.
[0316] A portion of each plasma sample was also sent to 3 outside analytical laboratories (San Diego Reference Laboratories, ARUP Laboratories, and NMS Labs) for quantification via the LC / MS reference method.
[0317] Four parameter logistic (4PL) curve fits were used to calibrate both assays. The 4PL calibration parameters for the methadone assay were: Bottom 148.5, Top 2520.0, IC50 199.4, and HillSlope -1.54. The 4PL calibration parameters for the EDDP assay were: Bottom 10.0, Top 1600.0, IC5025.0, and HillSlope -1.25.
[0318] Strong correlations were observed between CMAS results and LC / MS reference standard results for both the methadone and EDDP assays. The EDDP assay exhibited a coefficient of variation (CV) of approximately 11%. The trough to peak increase results are shown in Table 10.Table 10: Trough to peak concentration increases measured by CMAS for methadone and EDDP.EDDPPatient MTD Trough MTD Peak MTD % EDDP Peak EDDP % TroughID (ng / mL) (ng / mL) Increase (ng / mL) Increase (ng / mL)520 424 675 59 42 104 145 1219 635 1015 60 117 219 87 1218 688 774 13 100 171 71 4319 536 719 34 69 113 65 4330 354 510 44 42 84 101- 68 - 132621-0010W001 / 10715598.10Attomey Docket No. 132621 -0010WO01
[0319] The methadone assay results increased by an average of 42% from trough to peak, while the EDDP assay results increased by an average of 94% from trough to peak. In every case, for each assay and each patient, the concentrations measured by CMAS increased from trough to peak. These results demonstrated the feasibility of detecting that a methadone dose has been taken by comparing trough and peak concentrations of methadone and EDDP using the lateral flow test system at the point of care.- 69 - 132621-0010W001 / 10715598.10
Claims
Attomey Docket No. 132621 -0010WO01CLAIMS1. A method for quantifying methadone in a blood or plasma sample, said method comprising:obtaining a blood or plasma sample from a subject;contacting the blood or plasma sample:(i) with a pre-mix buffer to form a pre-mixed sample and loading the pre-mixed sample onto a lateral flow device;(ii) directly onto a lateral flow device followed by a chase buffer; or(iii) directly onto a lateral flow device;wherein the lateral flow device comprises:a flow path for receiving a fluid sample;a sample receiving zone coupled to the flow path;a labeled anti -methadone antibody coupled to the flow path upstream of a first detection zone; anda first detection zone coupled to the flow path downstream of the sample receiving zone and comprising an immobilized methadone-bovine serum albumin (BSA) conjugate, wherein the methadone-BSA conjugate has a methadone to BSA conjugation ratio within the range of 15 : 1 to 1:1;wherein the labeled anti-methadone antibody that is unbound to methadone is configured to flow in the flow path to the first detection zone, is captured at the first detection zone, and emits a detectable signal, andwherein the labeled anti-methadone antibody that is specifically bound to the methadone in the blood or plasma sample is configured to flow in the flow path past the first detection zone when the fluid sample is received on the lateral flow device;detecting a signal intensity from the labeled anti-methadone antibody bound to the immobilized methadone-BSA conjugate in the first detection zone; and- 70 - 132621-0010W001 / 10715598.10Attorney Docket No. 132621 -0010WO01determining the concentration of methadone based on the detected signal intensity from the first detection zone by converting the measured detected signal intensity to a methadone concentration using a dose response curve.
2. The method of claim 1, wherein a pre-mix buffer, chase buffer, and / or flow path chemistry dispensed upstream of the detection zone of the lateral flow device comprises one or more of a blocking protein, a surfactant, a chelating agent, a salt, and a buffering agent.
3. The method of claim 1 or 2, wherein the pre-mix running buffer comprises phosphate buffered saline, Tween-20, and a preservative at a pH of 7.0 to 8.0.
4. The method of any one of claims 1-3, wherein the concentration of methadone is quantified with a coefficient of variation (CV) of less than a value selected from the group consisting of: 20%, 15%, 10%, and 5%.
5. The method of any one of claims 1-4, wherein the lateral flow device further comprises a control-line zone, wherein the labeled anti-methadone antibody that is bound to methadone present in the sample is captured at the control-line zone and emits a detectable control signal.
6. The method of any one of claims 1-5, wherein the anti-methadone antibody is conjugated to a detectable label comprising gold nanoparticles.
7. The method of any one of claims 1-6, wherein the signal intensity is detected using a reader comprising a light source and a detector, and a data analyzer configured to convert the detected signal intensity to the methadone concentration based on the dose response curve.
8. The method of any one of claims 1-7, wherein the methadone concentration quantified is within a range of 75 ng / mL to 1600 ng / mL.
9. The method of any one of claims 1-8, wherein the blood or plasma sample is a fingerstick capillary blood sample.- 71 - 132621-0010W001 / 10715598.10Attomey Docket No. 132621 -0010WO0110. The method of any one of claims 1-9, wherein the sample volume is approximately 5 pL of plasma mixed with approximately 95 pL of pre-mix running buffer to form a total assay volume of approximately 100 pL.
11. The method of any one of claims 1-10, wherein the lateral flow device comprises a nitrocellulose membrane comprising a CN140 membrane.
12. The method of any one of claims 1-11, wherein the lateral flow device comprises a conjugate pad pretreated with a pretreatment buffer, wherein the pretreatment buffer comprises a surfactant, a buffering agent, and a blocking protein.
13. The method of claim 6, wherein the gold nanoparticles have a diameter of approximately 40 nm.
14. The method of any one of claims 1-13, wherein the dose response curve is generated using a four-parameter logistic (4PL) curve fit.
15. The method of any one of claims 1-14, further comprising determining a methadone concentration from the dose response curve within 30 minutes of loading the premixed sample onto the lateral flow device.
16. The method of any one of claims 1-14, further comprising determining a methadone concentration from the dose response curve within 15 minutes of loading the premixed sample onto the lateral flow device.
17. A test system for quantifying methadone in a blood or plasma sample, said test system comprising:a kit comprising a pre-mix running buffer configured to form a pre-mixed sample when contacted with a blood or plasma sample;a lateral flow device comprising:a flow path for receiving a fluid sample;a sample receiving zone coupled to the flow path;- 72 - 132621-0010W001 / 10715598.10Attorney Docket No. 132621 -0010WO01a labeled anti -methadone antibody coupled to the flow path upstream of a first detection zone; anda first detection zone coupled to the flow path downstream of the sample receiving zone and comprising an immobilized methadone-bovine serum albumin (BSA) conjugate, wherein the methadone-BSA conjugate has a methadone to BSA conjugation ratio within the range of 15 : 1 to 1:1; anda reader comprising a light source and a detector, and a data analyzer.
18. The test system of claim 17, wherein the labeled anti-methadone antibody that is unbound to methadone is configured to flow in the flow path to the first detection zone and is captured by the immobilized methadone-BSA conjugate at the first detection zone and emits a detectable signal.
19. The test system of claim 17 or 18, wherein the labeled anti-methadone antibody specifically bound to the methadone in the blood or plasma sample is configured to flow in the flow path past the first detection zone when the fluid sample is received on the lateral flow device.
20. The test system of any one of claims 17-19, wherein the lateral flow device further comprises:a labeled anti-EDDP antibody coupled to the flow path upstream of a second detection zone; anda second detection zone coupled to the flow path downstream of the sample receiving zone and comprising an immobilized EDDP-BSA conjugate, wherein the EDDP-BSA conjugate has an EDDP to B SA conjugation ratio within the range of 15 : 1 to 1 : 1.
21. The test system of claim 20, wherein the labeled anti-EDDP antibody that is unbound to EDDP is configured to flow in the flow path to the second detection zone, is captured at the second detection zone, and emits a detectable signal.
22. The test system of claim 20 or 21, wherein the data analyzer is configured to calculate a methadone to metabolite ratio (MMR) based on a concentration of methadone - 73 - 132621-0010W001 / 10715598.10Attomey Docket No. 132621 -0010WO01detected at the first detection zone and a concentration of EDDP detected at the second detection zone.
23. The test system of any one of claims 17-22, wherein the reader comprises an iPeak reader configured to generate an iPeak Area Score corresponding to the signal intensity at each detection zone.
24. The test system of any one of claims 17-23, further comprising a lancet for obtaining a capillary blood sample from a fingertip of a subject.
25. The test system of claim 22, wherein the data analyzer is configured to assign the patient to a metabolic category selected from the group consisting of ultra-rapid metabolizer (URM), extensive metabolizer (EM), intermediate metabolizer (IM), and ultraslow metabolizer (USM) based on the MMR.
26. The test system of any one of claims 17-25, wherein the data analyzer is configured to analyze reader data using a four-parameter logistic (4PL) curve fit to generate the dose response curve.
27. The test system of any one of claims 17-26, wherein the lateral flow device further comprises a sample pad comprising a blood separation pad configured to separate cellular components from plasma.
28. The test system of claim 20, wherein the lateral flow device is configured to quantify methadone within a range of 75 ng / mL to 1600 ng / mL and EDDP within a range of 5 ng / mL to 500 ng / mL.
29. A lateral flow test strip device for quantifying methadone and EDDP in a blood or plasma sample, wherein said device comprises:a flow path for receiving a fluid sample;a sample receiving zone coupled to the flow path;a labeled anti -methadone antibody coupled to the flow path upstream of a first detection zone;- 74 - 132621-0010W001 / 10715598.10Attorney Docket No. 132621 -0010WO01a first detection zone coupled to the flow path downstream of the sample receiving zone and comprising an immobilized methadone-bovine serum albumin (BSA) conjugate, wherein the methadone-BSA conjugate has a methadone to BSA conjugation ratio within the range of 15 : 1 to 1:1;a labeled anti-EDDP antibody coupled to the flow path upstream of a second detection zone; anda second detection zone coupled to the flow path downstream of the sample receiving zone and comprising an immobilized EDDP-BSA conjugate, wherein the EDDP-BSA conjugate has an EDDP to BSA conjugation ratio within the range of 15: 1 to 1 : 1;wherein the labeled anti-methadone antibody that is unbound to methadone is configured to flow in the flow path to the first detection zone and is captured by the immobilized methadone-BSA conjugate at the first detection zone and emits a detectable signal, andwherein the labeled anti-methadone antibody specifically bound to the methadone in the blood or plasma sample is configured to flow in the flow path past the first detection zone when the fluid sample is received on the lateral flow device.
30. The lateral flow test strip device of claim 29, wherein the labeled anti-EDDP antibody that is unbound to EDDP is configured to flow in the flow path to the second detection zone, is captured at the second detection zone, and emits a detectable signal.
31. The lateral flow test strip device of claim 29 or 30, wherein the labeled anti-EDDP antibody that is specifically bound to the EDDP in the blood or plasma sample is configured to flow in the flow path past the second detection zone when the fluid sample is received on the lateral flow device.
32. The lateral flow test strip device of any one of claims 29-31, further comprising a control-line zone positioned downstream of the first detection zone and the second detection zone, wherein the control-line zone comprises a goat anti-mouse antibody configured to- 75 - 132621-0010W001 / 10715598.10Attomey Docket No. 132621 -0010WO01capture labeled antibody that has flowed through the first detection zone and the second detection zone.
33. The lateral flow test strip device of any one of claims 29-32, wherein the labeled anti-methadone antibody and the labeled anti-EDDP antibody are each conjugated to gold nanoparticles.
34. The lateral flow test strip device of any one of claims 29-33, further comprising a conjugate pad configured to receive and release the labeled anti-methadone antibody and the labeled anti-EDDP antibody, wherein the conjugate pad is pretreated with a pretreatment buffer configured to facilitate release of the labeled antibodies when a sample is applied to the lateral flow test strip device.
35. The lateral flow test strip device of any one of claims 29-34, wherein the first detection zone is positioned upstream of the second detection zone along the flow path, or the second detection zone is positioned upstream of the first detection zone along the flow path.
36. The lateral flow test strip device of any one of claims 29-35, further comprising a nitrocellulose membrane having a width of approximately 25 mm, wherein the first detection zone and the second detection zone are positioned on the nitrocellulose membrane.
37. The lateral flow test strip device of claim 34, wherein the conjugate pad comprises an Ahlstrom 8980 conjugate pad comprising chopped glass fibers with a binder.
38. The lateral flow test strip device of claim 34 or 37, wherein the pretreatment buffer comprises Tergitol, HEPES, sodium tetraborate decahydrate, and BSA.
39. The lateral flow test strip device of any one of claims 29-38, further comprising a sample pad having a length of approximately 15 mm and an absorbent pad having a length of approximately 20 mm.
40. The lateral flow test strip device of claim 33, wherein the gold nanoparticles have a diameter of approximately 40 nm.- 76 - 132621-0010W001 / 10715598.10Attomey Docket No. 132621 -0010WO0141. The lateral flow test strip device of any one of claims 29-40, wherein the immobilized methadone-BSA conjugate is striped onto a nitrocellulose membrane at a concentration of approximately 0.25 mg / mL to approximately 0.5 mg / mL.
42. The lateral flow test strip device of any one of claims 29-41, wherein the immobilized EDDP-BSA conjugate is striped onto a nitrocellulose membrane at a concentration of approximately 0.125 mg / mL to approximately 0.5 mg / mL.
43. A kit for point-of-care quantification of methadone and EDDP in a blood or plasma sample, the kit comprising:a lateral flow test strip device comprising a flow path, a sample receiving zone, a labeled anti-methadone antibody upstream of a first detection zone comprising an immobilized methadone-BSA conjugate having a methadone to BSA conjugation ratio within the range of 15:1 to 1:1, a labeled anti -EDDP antibody upstream of a second detection zone comprising an immobilized EDDP-BSA conjugate having an EDDP to BSA conjugation ratio within the range of 15 : 1 to 1:1;a pre-mix running buffer configured to be contacted with the blood or plasma sample to form a pre-mixed sample prior to loading onto the lateral flow test strip device; and instructions for use.
44. The kit of claim 43, further comprising a reader comprising a light source and a detector, and a data analyzer configured to convert detected signal intensity to analyte concentration based on a dose response curve.
45. The kit of claim 43 or 44, further comprising a lancet for obtaining a capillary blood sample from a fingertip of a subject.
46. The kit of any one of claims 43-45, wherein the pre-mix running buffer comprises a carbonate buffer, a salt, a chelating agent, and a surfactant.
47. The kit of claim 44, wherein the data analyzer is configured to calculate a methadone to metabolite ratio (MMR) based on a concentration of methadone detected at the first detection zone and a concentration of EDDP detected at the second detection zone.- 77 - 132621-0010W001 / 10715598.10Attorney Docket No. 132621 -0010WO0148. The kit of claim 47, wherein the data analyzer is configured to assign a patient to a metabolic category selected from the group consisting of ultra-rapid metabolizer (URM), extensive metabolizer (EM), intermediate metabolizer (IM), and ultra-slow metabolizer (USM) based on the MMR.
49. The kit of any one of claims 43-48, wherein the lateral flow test strip device further comprises a control-line zone positioned downstream of the first detection zone and the second detection zone.
50. The kit of any one of claims 43-49, wherein the labeled anti -methadone antibody and the labeled anti-EDDP antibody are each conjugated to gold nanoparticles.
51. A method for quantifying EDDP in a blood or plasma sample, said method comprising:obtaining a blood or plasma sample from a subject;contacting the blood or plasma sample:(i) with a pre-mix buffer to form a pre-mixed sample and loading the pre-mixed sample onto a lateral flow device;(ii) directly onto a lateral flow device followed by a chase buffer; or(iii) directly onto a lateral flow device;wherein the lateral flow device comprises:a flow path for receiving a fluid sample;a sample receiving zone coupled to the flow path;a labeled anti-EDDP antibody coupled to the flow path upstream of a detection zone; anda detection zone coupled to the flow path downstream of the sample receiving zone and comprising an immobilized EDDP -bovine serum albumin (BSA) conjugate, wherein the EDDP-BSA conjugate has an EDDP to BSA conjugation ratio within the range of 15: 1 to 1 : 1;- 78 - 132621-0010W001 / 10715598.10Attomey Docket No. 132621 -0010WO01wherein the labeled anti-EDDP antibody that is unbound to EDDP is configured to flow in the flow path to the detection zone, is captured at the detection zone, and emits a detectable signal, andwherein the labeled anti-EDDP antibody that is specifically bound to the EDDP in the blood or plasma sample is configured to flow in the flow path past the detection zone when the fluid sample is received on the lateral flow device;detecting a signal intensity from the labeled anti-EDDP antibody bound to the immobilized EDDP -B SA conjugate in the detection zone; anddetermining the concentration of EDDP based on the detected signal intensity from the detection zone by converting the measured detected signal intensity to an EDDP concentration using a dose response curve.
52. The method of claim 51, wherein the concentration of EDDP is quantified with a coefficient of variation (CV) of less than a value selected from the group consisting of 20%, 15%, 10%, and 5%.
53. The method of claim 51 or 52, wherein the lateral flow device further comprises a control-line zone, wherein the labeled anti-EDDP antibody that is bound to EDDP present in the sample is captured at the control-line zone and emits a detectable control signal.
54. The method of any one of claims 51-53, wherein the anti-EDDP antibody is conjugated to a detectable label comprising gold nanoparticles.
55. The method of any one of claims 51-54, wherein the signal intensity is detected using a reader comprising a light source and a detector, and a data analyzer configured to convert the detected signal intensity to the EDDP concentration based on the dose response curve.
56. The method of any one of claims 51-55, wherein the EDDP concentration quantified is within a range of 5 ng / mL to 500 ng / mL.
57. A test system for quantifying EDDP in a blood or plasma sample, said test system comprising:- 79 - 132621-0010W001 / 10715598.10Attorney Docket No. 132621 -0010WO01a kit comprising a pre-mix running buffer configured to form a pre-mixed sample when contacted with a blood or plasma sample;a lateral flow device comprising:a flow path for receiving a fluid sample;a sample receiving zone coupled to the flow path;a labeled anti-EDDP antibody coupled to the flow path upstream of a detection zone; anda detection zone coupled to the flow path downstream of the sample receiving zone and comprising an immobilized EDDP -bovine serum albumin (BSA) conjugate, wherein the EDDP-BSA conjugate has an EDDP to BSA conjugation ratio within the range of 15: 1 to 1 : 1; anda reader comprising a light source and a detector, and a data analyzer.
58. The test system of claim 57, wherein the labeled anti-EDDP antibody that is unbound to EDDP is configured to flow in the flow path to the detection zone and is captured by the immobilized EDDP-BSA conjugate at the detection zone and emits a detectable signal.
59. The test system of claim 57 or 58, wherein the labeled anti-EDDP antibody specifically bound to the EDDP in the blood or plasma sample is configured to flow in the flow path past the detection zone when the fluid sample is received on the lateral flow device.
60. A lateral flow test strip device for quantifying EDDP in a blood or plasma sample, wherein said device comprises:a flow path for receiving a fluid sample;a sample receiving zone coupled to the flow path;a labeled anti-EDDP antibody coupled to the flow path upstream of a detection zone; and- 80 - 132621-0010W001 / 10715598.10Attorney Docket No. 132621 -0010WO01a detection zone coupled to the flow path downstream of the sample receiving zone and comprising an immobilized EDDP -bovine serum albumin (BSA) conjugate, wherein the EDDP-BSA conjugate has an EDDP to BSA conjugation ratio within the range of 15: 1 to 1 : 1;wherein the labeled anti-EDDP antibody that is unbound to EDDP is configured to flow in the flow path to the detection zone and is captured by the immobilized EDDP-BSA conjugate at the detection zone and emits a detectable signal, andwherein the labeled anti-EDDP antibody specifically bound to the EDDP in the blood or plasma sample is configured to flow in the flow path past the detection zone when the fluid sample is received on the lateral flow device.- 81 - 132621-0010W001 / 10715598.10
